<SEC-DOCUMENT>0001104659-22-115125.txt : 20221107
<SEC-HEADER>0001104659-22-115125.hdr.sgml : 20221107
<ACCEPTANCE-DATETIME>20221107072208
ACCESSION NUMBER:		0001104659-22-115125
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20221107
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20221107
DATE AS OF CHANGE:		20221107

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			AMICUS THERAPEUTICS, INC.
		CENTRAL INDEX KEY:			0001178879
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				200422823
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33497
		FILM NUMBER:		221363712

	BUSINESS ADDRESS:	
		STREET 1:		3675 MARKET STREET
		CITY:			PHILADELPHIA
		STATE:			PA
		ZIP:			19104
		BUSINESS PHONE:		(215) 921-7600

	MAIL ADDRESS:	
		STREET 1:		3675 MARKET STREET
		CITY:			PHILADELPHIA
		STATE:			PA
		ZIP:			19104

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AMICUS THERAPEUTICS INC
		DATE OF NAME CHANGE:	20020729
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>tm2229838d1_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:us-roles="http://fasb.org/us-roles/2021-01-31" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:fold="http://amicustherapeutics.com/20221107">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02A_US%2DGAAP%2D2021 -->
<!-- Field: Set; Name: xdx; ID: xdx_034_fold_amicustherapeutics.com_20221107 -->
<!-- Field: Set; Name: xdx; ID: xdx_040_20221107_20221107 -->
<!-- Field: Set; Name: xdx; ID: xdx_051_edei%2D%2DEntityCentralIndexKey_0001178879 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="From2022-11-07to2022-11-07" name="dei:EntityCentralIndexKey">0001178879</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2022-11-07to2022-11-07" name="dei:AmendmentFlag">false</ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="fold-20221107.xsd" xlink:type="simple" />
  </ix:references>
 <ix:resources>
    <xbrli:context id="From2022-11-07to2022-11-07">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-11-07</xbrli:startDate>
        <xbrli:endDate>2022-11-07</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="margin: 0">&#160;</p>

<p style="margin: 0"></p>

<!-- Field: Rule-Page --><div style="margin-top: 0; margin-bottom: 0; width: 100%"><div style="border-top: Black 2pt solid; border-bottom: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="margin: 0">&#160;</p>

<p style="font: 18pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>UNITED
STATES</b></p>

<p style="font: 18pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>SECURITIES
AND EXCHANGE COMMISSION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>WASHINGTON,
D.C. 20549</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; text-indent: -2px; margin-top: 0pt; margin-bottom: 0pt"><b></b>&#160;</p>

<p style="font: 18pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>FORM
<span id="xdx_906_edei--DocumentType_c20221107__20221107_z4EFEqmkFQ3e"><ix:nonNumeric contextRef="From2022-11-07to2022-11-07" name="dei:DocumentType">8-K</ix:nonNumeric></span></b></p>

<p style="font-size: 10pt; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 12pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>CURRENT
REPORT PURSUANT TO</b></p>

<p style="font: 12pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>SECTION
13 OR 15(d) OF THE</b></p>

<p style="font: 12pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>SECURITIES EXCHANGE ACT OF 1934</b></p>

<p style="font-size: 10pt; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Date of Report (Date of
earliest event reported):&#160;<b><span id="xdx_90F_edei--DocumentPeriodEndDate_c20221107__20221107_z2I1QiGpagYe"><ix:nonNumeric contextRef="From2022-11-07to2022-11-07" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate">November 7,
2022</ix:nonNumeric></span></b></p>

<p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>


<p style="font: 18pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b><span id="xdx_90E_edei--EntityRegistrantName_c20221107__20221107_zuO6AdsjGKb9"><ix:nonNumeric contextRef="From2022-11-07to2022-11-07" name="dei:EntityRegistrantName">AMICUS THERAPEUTICS, INC.</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">(Exact
Name of Registrant as Specified in  Its Charter)</p>

<p style="font-size: 10pt; text-align: center; text-indent: -2px; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; margin-right: auto; width: 100%; border-collapse: collapse; text-align: left">
<tr style="vertical-align: bottom">
    <td style="padding: 2px; text-align: center; width: 32%"><b><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90A_edei--EntityIncorporationStateCountryCode_c20221107__20221107_zopit2BcebAl"><ix:nonNumeric contextRef="From2022-11-07to2022-11-07" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode">Delaware</ix:nonNumeric></span></span></b></td>
    <td style="padding: 2px; text-align: left; width: 2%"><b>&#160;</b></td>
    <td style="padding: 2px; text-align: center; width: 32%"><span id="xdx_906_edei--EntityFileNumber_c20221107__20221107_zLIo2x30Dldj" style="font: 10pt Times New Roman, Times, Serif"><ix:nonNumeric contextRef="From2022-11-07to2022-11-07" name="dei:EntityFileNumber">001-33497</ix:nonNumeric></span></td>
    <td style="padding: 2px; text-align: left; width: 2%"><b>&#160;</b></td>
    <td style="padding: 2px; text-align: center; width: 32%"><span id="xdx_908_edei--EntityTaxIdentificationNumber_c20221107__20221107_zSR4rLLqJT07" style="font: 10pt Times New Roman, Times, Serif"><ix:nonNumeric contextRef="From2022-11-07to2022-11-07" name="dei:EntityTaxIdentificationNumber">71-0869350</ix:nonNumeric></span></td></tr>
<tr style="vertical-align: bottom">
    <td style="padding: 2px; text-align: center"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-style: normal"><b>(State
                                            or Other Jurisdiction</b></span></p>
        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-style: normal"><b>of Incorporation)</b></span></p></td>
    <td style="padding: 2px; text-align: center"><span style="font-style: normal"><b>&#160;</b></span></td>
    <td style="padding: 2px; text-align: center"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-style: normal"><b>(Commission</b></span></p>
        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-style: normal"><b>File Number)</b></span></p></td>
    <td style="padding: 2px; text-align: center"><span style="font-style: normal"><b>&#160;</b></span></td>
    <td style="padding: 2px; text-align: center"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-style: normal"><b>(I.R.S.
                                            Employer</b></span></p>
        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-style: normal"><b>Identification No.)</b></span></p></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; text-indent: 192px; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span id="xdx_90A_edei--EntityAddressAddressLine1_c20221107__20221107_zMR5s1IXepA2"><ix:nonNumeric contextRef="From2022-11-07to2022-11-07" name="dei:EntityAddressAddressLine1">3675 Market Street</ix:nonNumeric></span>,
<span id="xdx_907_edei--EntityAddressCityOrTown_c20221107__20221107_z07JE9pdWJO3"><ix:nonNumeric contextRef="From2022-11-07to2022-11-07" name="dei:EntityAddressCityOrTown">Philadelphia</ix:nonNumeric></span>, <span id="xdx_90E_edei--EntityAddressStateOrProvince_c20221107__20221107_zEKVNcBuhJLh"><ix:nonNumeric contextRef="From2022-11-07to2022-11-07" name="dei:EntityAddressStateOrProvince">PA</ix:nonNumeric></span> <span id="xdx_90C_edei--EntityAddressPostalZipCode_c20221107__20221107_zwqdUFd8RlDe"><ix:nonNumeric contextRef="From2022-11-07to2022-11-07" name="dei:EntityAddressPostalZipCode">19104</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>(Address of Principal
Executive Offices, and Zip Code)</b></p>

<p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span id="xdx_902_edei--CityAreaCode_c20221107__20221107_zV3MbYzxMdEf"><ix:nonNumeric contextRef="From2022-11-07to2022-11-07" name="dei:CityAreaCode">215</ix:nonNumeric></span>-<span id="xdx_902_edei--LocalPhoneNumber_c20221107__20221107_zKn7WYcJ3mX1"><ix:nonNumeric contextRef="From2022-11-07to2022-11-07" name="dei:LocalPhoneNumber">921-7600</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>Registrant&#8217;s
Telephone Number, Including Area Code</b></p>

<p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Former Name or Former Address, if Changed Since
Last Report.)</p>

<p style="font-size: 10pt; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="margin-left: 0.5in; font-size: 10pt; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p>

<p style="font-size: 10pt; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Wingdings"><span id="xdx_90D_edei--WrittenCommunications_c20221107__20221107_zgMss3yqzgbk"><ix:nonNumeric contextRef="From2022-11-07to2022-11-07" format="ixt:booleanfalse" name="dei:WrittenCommunications">&#168;</ix:nonNumeric></span></span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></td></tr>

<tr style="vertical-align: top">
    <td><span style="font-family: Wingdings"><span style="font-family: Wingdings"><span id="xdx_901_edei--SolicitingMaterial_c20221107__20221107_zZVy4lB2mUCi"><ix:nonNumeric contextRef="From2022-11-07to2022-11-07" format="ixt:booleanfalse" name="dei:SolicitingMaterial">&#168;</ix:nonNumeric></span></span></span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td></tr>

<tr style="vertical-align: top">
    <td><span style="font-family: Wingdings"><span id="xdx_900_edei--PreCommencementTenderOffer_c20221107__20221107_zsC1xvwjI985"><ix:nonNumeric contextRef="From2022-11-07to2022-11-07" format="ixt:booleanfalse" name="dei:PreCommencementTenderOffer">&#168;</ix:nonNumeric></span></span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr>

<tr style="vertical-align: top">
    <td><span style="font-family: Wingdings"><span id="xdx_908_edei--PreCommencementIssuerTenderOffer_c20221107__20221107_zv5OQ6ZjeWy2"><ix:nonNumeric contextRef="From2022-11-07to2022-11-07" format="ixt:booleanfalse" name="dei:PreCommencementIssuerTenderOffer">&#168;</ix:nonNumeric></span></span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">Securities registered pursuant
to Section 12(b) of the Act:</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; margin-right: auto; width: 100%; border-collapse: collapse; text-align: left">
<tr style="vertical-align: bottom">
    <td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-top: 2px; padding-right: 2px; padding-left: 2px; text-align: center; width: 32%"><span style="font: normal 10pt Times New Roman, Times, Serif">Title
    of each class</span></td>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-bottom: 1pt; width: 2%"><span style="font-style: normal; font-weight: normal">&#160;</span></td>
    <td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 2px; padding-right: 2px; padding-left: 2px; text-align: center; width: 32%"><span style="font: normal 10pt Times New Roman, Times, Serif">Trading
    Symbol(s)</span></td>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-bottom: 1pt; width: 2%"><span style="font-style: normal; font-weight: normal">&#160;</span></td>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 2px; padding-right: 2px; padding-left: 2px; text-align: center; width: 32%"><p style="margin-top: 0; margin-bottom: 0"><span style="font: normal 10pt Times New Roman, Times, Serif">Name
                                            of each exchange on which registered</span></p></td></tr>
<tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding: 2px; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_905_edei--Security12bTitle_c20221107__20221107_znyGe3zHmsMd"><ix:nonNumeric contextRef="From2022-11-07to2022-11-07" name="dei:Security12bTitle">Common Stock Par Value $0.01</ix:nonNumeric></span></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid">&#160;</td>
    <td style="border-bottom: Black 1pt solid; padding: 2px; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_900_edei--TradingSymbol_c20221107__20221107_zl405Poua3M3"><ix:nonNumeric contextRef="From2022-11-07to2022-11-07" name="dei:TradingSymbol">FOLD</ix:nonNumeric></span></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid">&#160;</td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 2px; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_901_edei--SecurityExchangeName_c20221107__20221107_z98kULbtQxi5"><ix:nonNumeric contextRef="From2022-11-07to2022-11-07" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName">NASDAQ</ix:nonNumeric></span></span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (17 CFR &#167;230.405) or Rule 12b-2 of the Securities Exchange Act of 1934
(17 CFR &#167;240.12b-2). Emerging growth company <span id="xdx_905_edei--EntityEmergingGrowthCompany_c20221107__20221107_zGm1cgX790wf" style="font-family: Wingdings"><ix:nonNumeric contextRef="From2022-11-07to2022-11-07" format="ixt:booleanfalse" name="dei:EntityEmergingGrowthCompany">&#168;</ix:nonNumeric></span></p>

<p style="font-size: 10pt; text-align: right; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">If an emerging growth company, indicate
by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act. <span style="font-family: Wingdings">&#168;</span></p>

<p style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="margin-top: 0pt; margin-bottom: 0pt"></p>

<!-- Field: Rule-Page --><div style="margin-top: 0; margin-bottom: 0; width: 100%"><div style="border-top: Black 1pt solid; border-bottom: Black 2pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="margin-top: 0pt; margin-bottom: 0pt"></p>

<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b>Item 1.01 &#8211; Entry into a Material Definitive
Agreement.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On November&#160;7,
2022, Amicus Therapeutics,&#160;Inc. (the &#8220;<b><i>Company</i></b>&#8221;) entered into an Equity Distribution Agreement (the
&#8220;<b><i>Distribution Agreement</i></b>&#8221;) with Goldman Sachs&#160;&amp; Co. LLC (&#8220;<b><i>Goldman
Sachs</i></b>&#8221;) to create an at-the-market equity program under which the Company at its discretion and from time to time may
 sell shares of its common stock, par value $0.01 per share, having an aggregate offering price of up to $250,000,000 (the
&#8220;<b><i>Shares</i></b>&#8221;) through Goldman Sachs.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">From time to time during the
term of the Distribution Agreement, the Company may deliver a placement notice to Goldman Sachs specifying the number of the Shares to
be sold, the price to be paid to the Company for such Shares, any provisions relating to rights of, and default by, underwriters acting
together with Goldman Sachs in the reoffering of the Shares, and the time,  date and place of delivery of and payment for such Shares.
Subject to the terms and conditions of the Distribution Agreement, and upon acceptance of a placement notice, Goldman Sachs will use its
reasonable efforts to sell the Shares based upon the Company&#8217;s instructions. The Company has provided Goldman Sachs with customary
indemnification rights, and Goldman Sachs will be entitled to  compensation at a commission rate of up to 3.0% of the gross offering proceeds of the Shares sold.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Sales of the Shares, if any,
under the Distribution Agreement may be made in transactions that are deemed to be &#8220;at the market offerings&#8221; as defined in
Rule&#160;415 under the Securities Act of 1933, as amended (the &#8220;<b><i>Securities Act</i></b>&#8221;), including in ordinary brokers&#8217; transactions, to or through a market maker, on or through The Nasdaq Global Select Market or any other market
venue where the securities may be traded, in the over-the-counter market, in privately negotiated transactions, through a combination
of any such methods of sale, or any other method permitted by law.
The Company has no obligation to sell any of the Shares, and may at any time suspend offers under the Distribution Agreement and either the Company or Goldman Sachs may at any time upon written notice terminate
the Distribution Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This description of the Distribution
Agreement does not purport to be complete and is qualified in its entirety by reference to the Distribution Agreement which is attached
hereto as Exhibit&#160;1.1 and incorporated by reference herein. The representations, warranties and covenants contained in the Distribution
Agreement were made only for purposes of such agreement and as of specific dates, were solely for the benefit of the parties to the Distribution
Agreement, and may be subject to limitations agreed upon by the contracting parties. Accordingly, the Distribution Agreement is incorporated
herein by reference only to provide investors with information regarding the terms of the Distribution Agreement and not to provide investors
with any other factual information regarding the Company or its business, and should be read in conjunction with the disclosures in the
Company&#8217;s periodic reports and other filings with the Securities and Exchange Commission.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The issuance and sale of the
Shares to be sold under the Distribution Agreement, if any, will be made pursuant to a prospectus supplement to the Company&#8217;s registration
statement on Form&#160;S-3,&#160;including the prospectus contained therein, originally filed with the Securities and Exchange Commission
on February&#160;24, 2022, which became effective automatically upon the filing thereof (Registration&#160;No.&#160;333-262987). This
Current Report on Form&#160;8-K shall not constitute an offer to sell or the solicitation of an offer to buy the Shares nor shall there
be any sale of the Shares in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification
under the securities laws of any such state.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">A copy of the legal opinion and consent of Troutman Petter Hamilton Sanders LLP relating to the Shares is attached as Exhibit 5.1 hereto.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b>Item 9.01 Financial Statements and Exhibits</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><b>(d)&#160;Exhibits:</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; width: 14%; text-align: center"><b>Exhibit&#160;No.</b></td>
    <td style="border-bottom: Black 1pt solid; width: 86%; text-align: center"><b>Description</b></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
  <tr>
    <td style="text-align: center"><a href="tm2229838d1_ex1-1.htm" style="-sec-extract: exhibit">1.1</a></td>
    <td style="vertical-align: bottom"><a href="tm2229838d1_ex1-1.htm" style="-sec-extract: exhibit">Equity Distribution Agreement, dated November&#160;7, 2022, by and between Amicus Therapeutics,&#160;Inc. and Goldman Sachs&#160;&amp; Co. LLC</a></td></tr>
  <tr>
    <td style="text-align: center"><a href="tm2229838d1_ex5-1.htm" style="-sec-extract: exhibit">5.1</a></td>
    <td style="vertical-align: bottom"><a href="tm2229838d1_ex5-1.htm" style="-sec-extract: exhibit">Opinion of Troutman Pepper Hamilton Sanders LLP</a></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><a href="tm2229838d1_ex5-1.htm">23.1</a></td>
    <td><a href="tm2229838d1_ex5-1.htm">Consent of Troutman Pepper Hamilton Sanders LLP (included in Exhibit&#160;5.1)</a></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">104</td>
    <td>Cover Page&#160;Interactive Data File (embedded within the Inline XBRL document)</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"></p>

<!-- Field: Page; Sequence: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b><span style="text-decoration: underline">Signature Page</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.25in">Pursuant to the requirements of the
Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly
authorized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td colspan="2">AMICUS THERAPEUTICS,&#160;INC.</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td colspan="2">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="width: 50%">Date: November&#160;7, 2022</td>
    <td style="width: 3%">By:</td>
    <td style="border-bottom: Black 1pt solid; width: 47%">/s/ Ellen S. Rosenberg</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td colspan="2">Name: Ellen S. Rosenberg</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td colspan="2">Title: Chief Legal Officer and Corporate Secretary</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

</body>
</html>
<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJxFjV0KwjAQhE/QOyx5Fk0KovbRokWsIkXE19iuEmyzZRP/juQtjS3isrAsM9+MEAOR0dLUyHCcFznssWlr7REKPCOjLTE40tU6gXALvBjnWVvfvT8wpcBgYMZDeSqD0FnvxmGVgJyO5GSkZiBniVKw24joq6dkz6ZC642uQdsKdkwtG/SaX33CXj/JUvPqqg7IzpBNQA1lL78hliqGLd31g/jqIM9TEQ26iUTGdGu/NTfnqYFFjU3ocj363+gDPyxJhA== -->
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-1.1
<SEQUENCE>2
<FILENAME>tm2229838d1_ex1-1.htm
<DESCRIPTION>EXHIBIT 1.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: right; margin: 0"><B>Exhibit 1.1</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; text-transform: uppercase"><B>Amicus
Therapeutics,&nbsp;Inc.</B></FONT><BR>
Common Stock ($0.01 par value)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Having an Aggregate Offering Price of up to</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">$250 million</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Equity Distribution Agreement</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">November&nbsp;7, 2022</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Goldman Sachs&nbsp;&amp; Co. LLC</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">200 West Street</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">New York, New York 10282</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Ladies and Gentlemen:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Amicus Therapeutics,&nbsp;Inc.,
a Delaware corporation (the &ldquo;<B>Company</B>&rdquo;) confirms its agreement (this &ldquo;<B>Agreement</B>&rdquo;) with Goldman Sachs&nbsp;&amp;
Co. LLC (&ldquo;<B>Goldman</B>&rdquo;), (the &ldquo;<B>Manager</B>&rdquo;) as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Description
of Shares</U>. The Company proposes to issue and sell through or to the Manager, as sales agent and/or principal, shares of the Company&rsquo;s
common stock, $0.01 par value (the &ldquo;<B>Common Stock</B>&rdquo;) having an aggregate offering price of up to $250 million (the &ldquo;<B>Shares</B>&rdquo;),
from time to time during the term of this Agreement and on the terms set forth in Section&nbsp;3 of this Agreement. The Company hereby
appoints the Manager as exclusive agent of the Company for the purpose of making offers and sales of the Shares. The Company agrees that
whenever it determines to sell the Shares directly to the Manager as principal, it will enter into a separate agreement (each, a &ldquo;<B>Terms
Agreement</B>&rdquo;) in substantially the form of Annex I hereto, relating to such sale in accordance with Section&nbsp;3 of this Agreement.
Certain terms used herein are defined in Section&nbsp;19 hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Representations
and Warranties</U>. The Company represents and warrants to, and agrees with, the Manager at the Execution Time and on each such time the
following representations and warranties are repeated or deemed to be made pursuant to this Agreement, as set forth below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Form&nbsp;S-3</U>.
 &nbsp;The Company meets the requirements for use of Form&nbsp;S-3 under the Act and has prepared and filed with the Commission an automatic
shelf registration statement (File Number 333-262987) on Form&nbsp;S-3, including a related Base Prospectus, for registration under the
Act of the offering and sale of the Shares and other securities of the Company. Such Registration Statement, including any amendments
thereto filed prior to the Execution Time or prior to any such time this representation is repeated or deemed to be made, automatically
became effective on February&nbsp;24, 2022 and no stop order suspending the effectiveness of the Registration Statement has been issued
under the Act and no proceedings for that purpose have been instituted or are pending or, to the knowledge of the Company, are contemplated
or threatened by the Commission, and any request on the part of the Commission for additional or supplemental information has been complied
with. The Company shall file with the Commission the Prospectus Supplement relating to the Shares in accordance with Rule&nbsp;424(b)&nbsp;promptly
after the Execution Time (but in any event in the time period prescribed by Rule&nbsp;424(b)). As filed, the Prospectus will contain all
information required by the Act and the rules&nbsp;thereunder, and, except to the extent the Manager shall agree in writing to a modification,
shall be in all substantive respects in the form furnished to the Manager prior to the Execution Time or prior to any such time this representation
is repeated or deemed to be made. The Registration Statement, at the Execution Time, each such time this representation is repeated or
deemed to be made, and at all times during which a prospectus is required by the Act to be delivered (whether physically or through compliance
with Rule&nbsp;172 or any similar rule) in connection with any offer or sale of Shares, meets the requirements set forth in Rule&nbsp;415(a)(1)(x).
The initial Effective Date of the Registration Statement was not earlier than the date three years before the Execution Time. Any reference
herein to the Registration Statement, the Base Prospectus, the Prospectus Supplement, any Interim Prospectus Supplement or the Prospectus
shall be deemed to refer to and include the documents incorporated by reference therein pursuant to Item 12 of Form&nbsp;S-3 which were
filed under the Exchange Act on or before the Effective Date of the Registration Statement or the issue date of the Base Prospectus, the
Prospectus Supplement, any Interim Prospectus Supplement or the Prospectus, as the case may be; and any reference herein to the terms
 &ldquo;amend,&rdquo; &ldquo;amendment&rdquo; or &ldquo;supplement&rdquo; with respect to the Registration Statement, the Base Prospectus,
the Prospectus Supplement, any Interim Prospectus Supplement or the Prospectus shall be deemed to refer to and include the filing of any
document under the Exchange Act after the Effective Date of the Registration Statement or the issue date of the Base Prospectus, the Prospectus
Supplement, any Interim Prospectus Supplement or the Prospectus, as the case may be, deemed to be incorporated therein by reference. Notwithstanding
the foregoing, the representations and warranties in this subsection shall not apply to statements in or omissions from the Registration
Statement or any post-effective amendment or the Prospectus or any amendments or supplements thereto, made in reliance upon and in conformity
with information furnished to the Company in writing by the Manager relating to the Manager expressly for use therein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Successor
Registration Statement</U>. To the extent that the Registration Statement is not available for the sales of the Shares as contemplated
by this Agreement, the Company shall file a new registration statement with respect to any additional Common Stock necessary to complete
such sales of the Shares and shall cause such registration statement to become effective as promptly as practicable. After the effectiveness
of any such registration statement, all references to &ldquo;Registration Statement&rdquo; included in this Agreement shall be deemed
to include such new registration statement, including all documents incorporated by reference therein pursuant to Item 12 of Form&nbsp;S-3,
and all references to &ldquo;Base Prospectus&rdquo; included in this Agreement shall be deemed to include the final form of prospectus,
including all documents incorporated therein by reference, included in any such registration statement at the time such registration statement
became effective.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>No
Material Misstatements or Omissions in the Registration Statement</U>. On each Effective Date, at the Execution Time, at each deemed effective
date with respect to the Manager pursuant to Rule&nbsp;430B(f)(2)&nbsp;under the Act, at each Applicable Time, at each Settlement Date,
at each Time of Delivery and at all times during which a prospectus is required by the Act to be delivered (whether physically or through
compliance with Rule&nbsp;172 or any similar rule) in connection with any offer or sale of Shares, the Registration Statement complied
and will comply in all material respects with the applicable requirements of the Act and the rules&nbsp;thereunder and did not and will
not contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary in order
to make the statements therein not misleading; and on the date of any filing pursuant to Rule&nbsp;424(b), at each Applicable Time, on
each Settlement Date, at each Time of Delivery and at all times during which a prospectus is required by the Act to be delivered (whether
physically or through compliance with Rule&nbsp;172 or any similar rule) in connection with any offer or sale of Shares, the Prospectus
(together with any supplement thereto) complied and will comply in all material respects with the applicable requirements of the Act and
the rules&nbsp;thereunder and did not and will not include any untrue statement of a material fact or omit to state a material fact necessary
in order to make the statements therein, in the light of the circumstances under which they were made, not misleading; <I>provided</I>,
<I>however</I>, that the Company makes no representations or warranties as to the information contained in or omitted from the Registration
Statement or the Prospectus (or any supplement thereto) in reliance upon and in conformity with information furnished in writing to the
Company by the Manager specifically for inclusion in the Registration Statement or the Prospectus (or any supplement thereto).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Disclosure
Package</U>. At the Execution Time, at each Applicable Time, at each Settlement Date and each Time of Delivery, the Disclosure Package
does not contain any untrue statement of a material fact or omit to state any material fact necessary in order to make the statements
therein, in the light of the circumstances under which they were made, not misleading. The preceding sentence does not apply to statements
in or omissions from the Disclosure Package based upon and in conformity with written information furnished to the Company by the Manager
specifically for use therein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Incorporated
Documents</U>. The documents incorporated or deemed to be incorporated by reference in the Registration Statement and the Prospectus (i)&nbsp;at
the time they were or hereafter are filed with the Commission, complied and will comply in all material respects with the requirements
of the Exchange Act and the rules&nbsp;and regulations of the Commission thereunder and (ii)&nbsp;when read together with the other information
in the Prospectus and the Disclosure Package at any Applicable Time and when read together with the other information in the Prospectus
at the date of the Prospectus and at any Settlement Date or Time of Delivery, will not include an untrue statement of a material fact
or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances under which they
were made, not misleading.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Ineligible
Issuer</U>. The Company is not an &ldquo;ineligible issuer&rdquo; (as defined in Rule&nbsp;405 under the Act).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Notice
of Other Sales</U>. Prior to the execution of this Agreement, the Company has not, directly or indirectly, offered or sold any Shares
by means of any &ldquo;prospectus&rdquo; (within the meaning of the Act) or used any &ldquo;prospectus&rdquo; (within the meaning of the
Act) in connection with the offer or sale of the Shares, and from and after the execution of this Agreement, the Company will not, directly
or indirectly, offer or sell any Shares by means of any &ldquo;prospectus&rdquo; (within the meaning of the Act) or use any &ldquo;prospectus&rdquo;
(within the meaning of the Act) in connection with the offer or sale of the Shares, other than the Prospectus, as amended or supplemented
from time to time in accordance with the provisions of this Agreement; the Company has not, directly or indirectly, prepared, used or
referred to any Issuer Free Writing Prospectus in connection with the offering and sale of the Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>No
Stop Orders</U>. The Registration Statement is not the subject of a pending proceeding or examination under Section&nbsp;8(d)&nbsp;or
8(e)&nbsp;of the Act, and the Company is not the subject of a pending proceeding under Section&nbsp;8A of the Act in connection with the
offering of the Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Regulation
M</U>. The Common Stock constitutes an &ldquo;actively-traded security&rdquo; exempted from the requirements of Rule&nbsp;101 of Regulation
M under the Exchange Act by subsection (c)(1)&nbsp;of such rule.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(j)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Sales
Agency Agreements</U>. The Company has not entered into any other sales agency agreements or other similar arrangements with any agent
or any other representative in respect of any at the market offering (within the meaning of Rule&nbsp;415(a)(4)&nbsp;under the Act) of
the Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(k)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Offering
Materials</U>. The Company has not distributed and will not distribute, prior to the termination of this Agreement, any offering material
in connection with the offering and sale of the Shares other than the Prospectus and any Issuer Free Writing Prospectus reviewed and consented
to by the Manager and identified in Schedule I hereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(l)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>No
Material Adverse Change in Business</U>. Neither the Company nor any of its subsidiaries has sustained since the date of the latest audited
financial statements included or incorporated by reference in the Disclosure Package and the Prospectus any material loss or interference
with its business from fire, explosion, flood or other calamity, whether or not covered by insurance, or from any labor dispute or court
or governmental action, order or decree, otherwise than as set forth or contemplated in the Disclosure Package and the Prospectus and,
since the respective dates as of which information is given in the Registration Statement, Disclosure Package and the Prospectus, there
has not been (A)&nbsp;any material change in the capital stock (other than as a result of (i)&nbsp;the exercise of any stock options or
restricted stock units (&ldquo;<B>RSUs</B>&rdquo;) outstanding as of the date of this Agreement or warrants outstanding as of the date
of this Agreement, (ii)&nbsp;the award of stock options or RSUs in the ordinary course of business pursuant to the Company&rsquo;s equity
incentive plans, (iii)&nbsp;the repurchase of shares of stock in connection with any early exercise of stock options by option holders
from employees terminating their service to the Company, in each case as such options, warrants and equity incentive plans are described
in the Disclosure Package or Prospectus or (iv)&nbsp;the issuance, if any, of stock upon conversion of Company securities as described
in the Disclosure Package or Prospectus), (B)&nbsp;any material change in the long-term debt of the Company or any of its subsidiaries,
(C)&nbsp;any material adverse change, or any development involving a prospective material adverse change in or affecting the condition
(financial or otherwise), management, earnings, business or properties of the Company and its subsidiaries, taken as a whole, whether
or not arising from transactions in the ordinary course of business, except as described in the Registration Statement, the Disclosure
Package and the Prospectus or (D)&nbsp;any dividend or distribution of any kind declared, paid or made by the Company to stockholders
of the Company, in each case other than as described in the Registration Statement, the Disclosure Package and the Prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(m)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Title
to Property</U>. The Company and its subsidiaries have good and marketable title in fee simple to all real property and good and marketable
title to all personal property owned by them, in each case free and clear of all liens, encumbrances and defects except as described in
the Registration Statement, the Disclosure Package and the Prospectus or as do not materially interfere with the use made and proposed
to be made of such property by the Company or any of its subsidiaries; and any real property and buildings held under lease by the Company
or any of its subsidiaries are held by them under valid, subsisting and enforceable leases or subleases (subject to bankruptcy, insolvency,
reorganization, moratorium or similar laws affecting creditors&rsquo; rights generally and to general equitable principles) with such
limitations on the Company or its subsidiaries as are not material and do not interfere with the use made and proposed to be made of such
leased real property by the Company or any of its subsidiaries.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(n)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Good
Standing</U>. Each of the Company and its subsidiaries has been duly incorporated or organized, is validly existing as a corporation or
other business entity in good standing under the laws of its jurisdiction of incorporation or organization, with the requisite power and
authority to enter into and perform its obligations under this Agreement, own its properties and conduct its business as described in
the Registration Statement, the Disclosure Package and the Prospectus, and has been duly qualified as a foreign corporation or other business
entity for the transaction of business and is in good standing under the laws of each other jurisdiction in which it owns or leases properties
or conducts any business so as to require such qualification, or is subject to no material liability or disability by reason of the failure
to be so qualified in any such jurisdiction except where the failure to be so qualified would not (i)&nbsp;have, individually or in the
aggregate, a material adverse effect on the condition (financial or otherwise), management, earnings, business or properties of the Company
and its subsidiaries taken as a whole or (ii)&nbsp;prevent the consummation of the transactions contemplated by this Agreement (the occurrence
of any such effect or any such prevention described in the foregoing clauses (i)&nbsp;and (ii)&nbsp;being referred to as a &ldquo;<B>Material
Adverse Effect</B>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(o)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Capitalization</U>.&nbsp;
The Company has an authorized capitalization as set forth in the Registration Statement, the Disclosure Package and the Prospectus and
all of the issued shares of capital stock of the Company have been duly and validly authorized and issued and are fully paid and non-assessable
and conform to the description thereof contained in the Registration Statement, the Disclosure Package and the Prospectus. Except as described
in the Registration Statement, the Disclosure Package and the Prospectus, all of the issued and outstanding capital stock of, or other
equity interests in, each subsidiary of the Company has been duly authorized and validly issued, is fully paid and non-assessable and
is owned by the Company, directly or through other subsidiaries of the Company, free and clear of any security interest, mortgage, pledge,
lien, encumbrance, claim or equity (other than restrictions on transfer under applicable securities laws).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(p)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Due
Authorization of the Shares</U>.&nbsp; The Shares have been duly and validly authorized and, when the Shares are issued and delivered
against payment therefor as provided herein, such Shares will be duly and validly issued and fully paid and non-assessable and will conform
to the description of the Common Stock contained in the Registration Statement, the Disclosure Package and the Prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(q)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>No
Preemptive or Registration Rights</U>.&nbsp; Except as described in the Registration Statement, the Disclosure Package and the Prospectus,
there are no (i)&nbsp;preemptive rights or other rights to subscribe for or to purchase or any restriction upon the voting or transfer
of, any equity securities of the Company or any of its subsidiaries or (ii)&nbsp;outstanding options or warrants to purchase any securities
of the Company or any of its subsidiaries. Neither the filing of the Registration Statement nor the offering or sale of the Shares as
contemplated by this Agreement gives rise to any rights for or relating to the registration of any securities of the Company, except such
rights as have been waived or satisfied.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(r)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>No
Conflict or Violation</U>.&nbsp; (i)&nbsp;The issue and sale of the Shares and the compliance by the Company with this Agreement will
not and (ii)&nbsp;the execution, delivery and performance of this Agreement and the consummation of the transactions contemplated herein
and in the Registration Statement, the Disclosure Package and the Prospectus (including the issuance and sale of the Shares and the application
of the use of the proceeds from the sale of the Shares as described therein under the caption &ldquo;Use of Proceeds&rdquo;) do not and
will not, whether with or without the giving of notice or passage of time or both, (A)&nbsp;conflict with or result in a breach or violation
of any of the terms or provisions of, or constitute a default under, any indenture, mortgage, deed of trust, loan agreement or other agreement
or instrument to which the Company or any of its subsidiaries is a party or by which the Company or any of its subsidiaries is bound or
to which any of the property or assets of the Company or any of its subsidiaries is subject, (B)&nbsp;result in any violation of the provisions
of the certificate of incorporation or by-laws (or similar organizational documents) of the Company or the corresponding governing documents
of any of its subsidiaries, or (C)&nbsp;result in the violation of any statute or any order, rule&nbsp;or regulation of any court or governmental
agency or body having jurisdiction over the Company, any of its subsidiaries or any of their respective properties, except, with respect
to clauses (A)&nbsp;and (C), such conflicts or violations that would not reasonably be expected to have a Material Adverse Effect; and
no consent, approval, authorization, order, registration or qualification of or with any such court or governmental agency or body having
jurisdiction over the Company, any of its subsidiaries or any of their respective properties is required for the issue and sale of the
Shares or the consummation by the Company of the transactions contemplated by this Agreement, except the registration under the Act of
the Shares, the approval by the Financial Industry Regulatory Authority (&ldquo;<B>FINRA</B>&rdquo;) of the terms and arrangements herein
and such consents, approvals, authorizations, registrations or qualifications as may be required under state securities or Blue Sky laws
in connection with the purchase and distribution of the Shares by the Manager.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(s)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Absence
of Violations, Defaults and Conflicts</U>. None of the Company or any of its subsidiaries is (i)&nbsp;in violation of its certificate
of incorporation or by-laws (or similar organizational documents), (ii)&nbsp;in default in the performance or observance of any material
obligation, agreement, covenant or condition contained in any indenture, mortgage, deed of trust, loan agreement, lease or other agreement
or instrument to which it is a party or by which it or any of its properties may be bound or (iii)&nbsp;in violation or default of any
law, statute, rule, regulation, judgment, order, writ or decree of any arbitrator, court, governmental agency or body having jurisdiction
over the Company, any of its subsidiaries or any of their respective properties, assets or operations, as applicable; except in the case
of (iii), for such defaults as would not, individually or in the aggregate, have Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(t)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Due
Authorization</U>. The execution and delivery of, and the performance by the Company of its obligations under, this Agreement (including
but not limited to the issuance and sale of the Shares and the use of proceeds from the sale of the Shares as described in the Registration
Statement, the Disclosure Package and the Prospectus under the caption &ldquo;Use of Proceeds&rdquo;) have been duly and validly authorized
by all necessary corporate action on the part of the Company and this Agreement has been duly executed and delivered by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(u)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Summaries
of Law and Documents</U>.&nbsp; The statements set forth in the Registration Statement, the Disclosure Package and the Prospectus under
the captions &ldquo;Description of Common Stock&rdquo;, insofar as they purport to constitute a summary of the terms of the Common Stock
and under the captions &ldquo;Business&mdash;Government Regulation&rdquo;, &ldquo;Business&mdash;Intellectual Property&rdquo;, &ldquo;Risk
Factors&mdash;Risks Related to our Products and the Regulatory Approval and Clinical Development of our Product Candidates&rdquo;, &ldquo;Risk
Factors&mdash;Risks Related to Our Intellectual Property&rdquo;, and &ldquo;Certain Relationships and Related Transactions and Director
Independence&rdquo;, insofar as such statements purport to constitute summaries of the terms of the statutes, rules&nbsp;or regulations,
legal or governmental proceedings, agreements or documents referred to therein, are accurate summaries of the terms of such statutes,
rules&nbsp;or regulations, legal or governmental proceedings, agreements or documents, in all material respects. All agreements expressly
referenced in the Registration Statement, the Disclosure Package and the Prospectus between the Company or any of its subsidiaries, on
the one hand, and any other party, on the other hand, are legal, valid and binding obligations of the Company or the relevant subsidiary
and, to the Company&rsquo;s knowledge, such other party, enforceable against the Company or the relevant subsidiary and such other party
in accordance with their respective terms, subject to bankruptcy, insolvency, reorganization, moratorium or similar laws affecting creditors&rsquo;
rights generally and to general equitable principles and except as rights to indemnity and contribution thereunder may be limited by applicable
law or policies underlying such law. Except as described in the Registration Statement, the Disclosure Package and the Prospectus, none
of the Company or any of its subsidiaries has sent or received any notice indicating the termination of or intention to terminate any
of the contracts or agreements referred to, described in or incorporated by reference in the Registration Statement, the Disclosure Package
and the Prospectus or filed as an exhibit Registration Statement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Filings
and Governmental Licenses</U>. The Company and its subsidiaries have filed or caused to be filed with the appropriate governmental entities
all forms, statements, reports, and documents (including all exhibits, amendments, and supplements thereto) (each a &ldquo;<B>Filing</B>&rdquo;)
required to be filed by it with respect to the respective businesses of the Company and its subsidiaries and each of their facilities
under all applicable laws and the respective rules&nbsp;and regulations thereunder, all of which complied in all respects with all applicable
requirements of the appropriate law and rules&nbsp;and regulations thereunder in effect on the date each such Filing was made, except
where the failure to do so would not reasonably be expected to have a Material Adverse Effect. The Company and its subsidiaries (i)&nbsp;hold
all licenses, registrations, certificates and permits from governmental authorities (collectively, &ldquo;<B>Governmental Licenses</B>&rdquo;)
which are necessary to the conduct of the business now operated by them, except for such Governmental Licenses the failure of which to
hold would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect, (ii)&nbsp;are in compliance
with the terms and conditions of all Governmental Licenses, and all Governmental Licenses are valid and in full force and effect, except
as would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect, and (iii)&nbsp;have not received
any written notice of proceedings relating to the revocation or modification of any Governmental License.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(w)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Payment
of Taxes</U>. The Company and each of its subsidiaries has filed all material U.S. federal, state, local and foreign tax returns which
have been required to be filed and have paid all taxes indicated by such returns and all assessments received by them or any of them to
the extent that such taxes have become due, except for any such taxes being contested in good faith and for which an adequate reserve
or accrual has been established in accordance with U.S. generally accepted principles of accounting (&ldquo;<B>GAAP</B>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(x)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Possession
of Intellectual Property</U>. The Company and its subsidiaries own, or have obtained valid and enforceable licenses for, the
inventions, patent applications (including provisional applications), patents, trademarks, service marks, business names, trade
names, service names, logos, slogans, registered and unregistered copyrights (including copyrights in software), trade secrets,
trade dress, domain names, technology, know-how (including other unpatented and/or unpatentable proprietary or confidential
information, systems or procedures) and other intellectual property described in the Registration Statement, the Disclosure Package,
and the Prospectus as being owned or licensed by them or which are necessary for the conduct of their respective businesses as
currently conducted or as currently proposed to be conducted as described in the Registration Statement, the Disclosure Package, and
the Prospectus (collectively, &ldquo;<B>Intellectual Property</B>&rdquo;). To the knowledge of the Company, there are no third
parties who have rights to any Intellectual Property, except for customary reversionary rights of third-party licensors with respect
to Intellectual Property that is disclosed in the Registration Statement, the Disclosure Package, and the Prospectus as licensed to
the Company or any of its subsidiaries, and the Company and each of its subsidiaries have secured assignments to their respective
title, rights and interests in the Intellectual Property from their respective employees, consultants, agents and contractors.
Except as described in the Registration Statement, the Disclosure Package, and the Prospectus, to the knowledge of the Company, no
third party has infringed, misappropriated, diluted or otherwise violated, or is infringing, misappropriating, diluting or otherwise
violating, any Intellectual Property. To the knowledge of the Company, neither the Company nor any of its subsidiaries is
infringing, misappropriating, diluting or otherwise violating, or has infringed, misappropriated, diluted or otherwise violated, any
intellectual property rights of third parties. The Company and its subsidiaries have not received any notice or are otherwise aware
of any facts which would form a reasonable basis for any claim or assertion that the Company currently, or in the future upon the
manufacturing or commercialization of any product or service described in the Registration Statement, the Disclosure Package, and
the Prospectus as under development, infringes, misappropriates, dilutes or otherwise violates any intellectual property rights of
third parties. Except as described in the Registration Statement, the Disclosure Package, and the Prospectus, the Company and each
of its subsidiaries is either the sole owner or a co-owner of the Intellectual Property owned by it and has the valid and
enforceable right to use such Intellectual Property without the obligation to obtain consent to sublicense and without a duty of
accounting to any co-owner, as applicable. Except as described in the Registration Statement, the Disclosure Package, and the
Prospectus, neither the Company nor any of its subsidiaries is obligated to pay a material royalty, grant a license or option, or
provide other material consideration to any third party in connection with the Intellectual Property owned by or licensed to the
Company or its subsidiaries. The Company and its subsidiaries have taken all reasonable and customary (for a company of the size of
the Company or its applicable subsidiary and operating in the industry in which the Company and its subsidiaries operate) steps to
protect, maintain and safeguard the Intellectual Property, including by implementation of physical and cyber security measures and
the execution of appropriate employment contracts, patent disclosure agreements, non-competition agreements, non-solicitation
agreements, nondisclosure agreements, and confidentiality agreements with their employees. To the Company&rsquo;s knowledge, no
employee of the Company or any of its subsidiaries is in or has been in violation of any term of any employment contract, patent
disclosure agreement, invention assignment agreement, non-competition agreement, non-solicitation agreement, nondisclosure agreement
or any restrictive covenant to or with a former employer where the basis of such violation relates to such employee&rsquo;s
employment with the Company or such subsidiary. Except as described in the Registration Statement, the Disclosure Package, and the
Prospectus, there is no pending or, to the Company&rsquo;s knowledge, threatened action, suit, proceeding or claim by others:
(A)&nbsp;challenging the Company&rsquo;s or any of its subsidiaries&rsquo; rights in or to any Intellectual Property, and the
Company is unaware of any facts which would form a reasonable basis for any such action, suit, proceeding or claim;
(B)&nbsp;challenging the validity, enforceability or scope of any Intellectual Property, and the Company is unaware of any facts
which would form a reasonable basis for any such action, suit, proceeding or claim; or (C)&nbsp;asserting that either the Company or
any of its subsidiaries infringes, misappropriates, dilutes or otherwise violates, or would, upon the manufacturing or
commercialization of any product or service described in the Registration Statement, the Disclosure Package, and the Prospectus as
under development, infringe, misappropriate, dilute or otherwise violate, any patent, trademark, trade name, service name,
copyright, trade secret or other proprietary rights of others, and the Company is unaware of any facts which would form a reasonable
basis for any such action, suit, proceeding or claim. The Intellectual Property has not been adjudged by a court of competent
jurisdiction to be invalid or unenforceable, in whole or in part, and the Company is unaware of any facts which would form a
reasonable basis for any such adjudication. The Company and each of its subsidiaries have materially complied with the terms of each
agreement pursuant to which Intellectual Property has been licensed to the Company or such subsidiary, and all such agreements are
in full force and effect. The product candidates described in the Registration Statement, the Disclosure Package, and the Prospectus
as under development by the Company fall within the scope of the claims of one or more patents or patent applications owned by, or
exclusively licensed to, the Company. No government funding, facilities or resources of a university, college, other educational
institution or research center was used in the development of any Intellectual Property that is owned or purported to be owned by
the Company or any of its subsidiaries that would confer any governmental agency or body, university, college, other educational
institution or research center any claim or right of ownership to any such Intellectual Property.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(y)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Patents</U>.
(i)&nbsp;All patents and patent applications owned by or exclusively licensed to the Company or its subsidiaries or under which the Company
or any of its subsidiaries has rights have, to the knowledge of the Company, been duly and properly filed and each issued patent is being
diligently maintained and is valid and enforceable, and the Company is unaware of any facts that would preclude the issuance of a valid
and enforceable patent on any pending patent application included in the Intellectual Property; (ii)&nbsp;to the knowledge of the Company,
the Company, its subsidiaries, and the parties prosecuting such applications have complied with their duty of candor and disclosure to
the U.S. Patent and Trademark Office (the &ldquo;USPTO&rdquo;) and to any relevant foreign patent authority having similar requirements
in connection with such patents and patent applications for which it has filing, prosecution, and/or maintenance responsibilities; and
(iii)&nbsp;the Company is not aware of any prior art or public or commercial activity or other facts required to be disclosed to the USPTO
or any relevant foreign patent authority that were not disclosed and which would preclude the grant of a patent in connection with any
such application or would reasonably be expected to form the basis of a finding of invalidity or unenforceability with respect to any
patents that have been issued with respect to such applications.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(z)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Regulatory
Compliance</U>. The Company has operated and currently is in compliance in all material respects with all applicable rules&nbsp;and regulations
of the United States Food and Drug Administration (the &ldquo;FDA&rdquo;) and other governmental agencies; (ii)&nbsp;the Company and its
subsidiaries (A)&nbsp;possess, and are in material compliance with the terms of, all material licenses, permits, approvals, certificates,
registrations, franchises, clearances, exemptions and other authorizations necessary to conduct their respective businesses (collectively,
 &ldquo;Licenses&rdquo;), including, without limitation, all Licenses required by the FDA and/or by any other governmental agencies, which
Licenses are in full force and effect, (B)&nbsp;have not received any notice from any governmental agency relating to the revocation or
modification of any Licenses that, if determined adversely to the Company or its subsidiaries, would reasonably be expected to have a
material impact on the Company and (C)&nbsp;are not aware of any other action by any governmental agency to limit, suspend, terminate
or revoke any License held by the Company or any of its subsidiaries; (iii)&nbsp;(A)&nbsp;the studies, tests and preclinical and clinical
trials conducted by or on behalf of or sponsored by the Company were, and if still pending are being, conducted in all material respects
in accordance with standard medical and scientific research procedures and controls, (B)&nbsp;none of the studies, tests and preclinical
and clinical trials conducted by or on behalf of or sponsored by the Company involved any investigator who has been disqualified as a
clinical investigator or has been found by the FDA to have engaged in scientific misconduct, (C)&nbsp;the Company is not aware of any
studies, tests or trials the results of which reasonably call into question the clinical trial results described or referred to in the
Registration Statement, Disclosure Package and the Prospectus and (D)&nbsp;except as disclosed in the Registration Statement, Disclosure
Package and the Prospectus, the Company and its subsidiaries have not received any communication, notice or correspondence from any governmental
agencies requiring the termination, material modification or suspension of any studies, tests or preclinical and clinical trials conducted
by or on behalf of or sponsored by the Company; (iv)&nbsp;each description of any studies, tests or preclinical and clinical trials conducted
by or on behalf of or sponsored by the Company contained in the Registration Statement, Disclosure Package and the Prospectus is accurate
and complete in all material respects and fairly presents the data about and derived from such studies, tests and trials and (v)&nbsp;all
manufacturing, packaging, processing, labeling, distribution, marketing, promotion, storage, import, export or disposal of the Company&rsquo;s
or its subsidiaries&rsquo; products by the Company, its subsidiaries or their suppliers, vendors or partners have been conducted in compliance
with all applicable laws, rules&nbsp;and regulations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(aa)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Privacy
Laws</U>. The Company and its subsidiaries are, and at all prior times were, in material compliance with all applicable data privacy and
security laws and regulations, including without limitation, as applicable, the General Data Protection Regulation 2016/679 (the &ldquo;GDPR&rdquo;),
the UK Data Protection Act 2018 (&ldquo;DPA&rdquo;), the UK General Data Protection Regulation as defined by the DPA as amended by the
Data Protection, Privacy and Electronic Communications (Amendments etc) (EU Exit) Regulations 2019 (together with the DPA, the &ldquo;UK
GDPR&rdquo;), and HIPAA, as amended by HITECH (collectively, &ldquo;Privacy Laws&rdquo;). To ensure compliance with the Privacy Laws,
and contractual obligations, industry standards, and any other legal obligations related to data privacy and security, the Company and
its subsidiaries have in place, comply with, and take appropriate steps reasonably designed to ensure compliance in all material respects
with their policies and procedures relating to data privacy and security and the collection, storage, use, disclosure, handling, and analysis
of Personal Data (the &ldquo;Policies&rdquo;) as applicable. &ldquo;Personal Data&rdquo; means all personal, personally identifiable,
sensitive, confidential or regulated data. The Company and its subsidiaries since inception have at all times made all disclosures to
users or customers required by applicable Privacy Laws, and have provided accurate notice of their respective Policies then in effect
to its customers, employees, third party vendors and representatives as required by applicable Privacy Laws, except where the failure
to do so would not, individually or in the aggregate, have a Material Adverse Effect. None of such disclosures made or contained in any
of the Policies have been inaccurate, misleading, deceptive or in violation of any Privacy Laws or Policies in any material respect. The
Company further certifies that neither it nor any subsidiary: (i)&nbsp;has received written notice of any actual or potential liability
under or relating to, or actual or potential material violation of, any of the Privacy Laws, and has no knowledge of any event or condition
that would reasonably be expected to result in any such notice; (ii)&nbsp;is currently conducting or paying for, in whole or in part,
any investigation, remediation, or other corrective action pursuant to any Privacy Law; or (iii)&nbsp;is a party to any order, decree,
or agreement that imposes any obligation or liability under any Privacy Law. The execution, delivery and performance of this Agreement
or any other agreement referred to in this Agreement will not result in a breach of violation of any Privacy Laws or Policies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(bb)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>IT
Systems</U>. Except as would not have a Material Adverse Effect, none of the material Intellectual Property employed by or on behalf of
the Company or any of its subsidiaries has been obtained or is being used by the Company or any of its subsidiaries in violation of any
contractual obligation binding on the Company, its subsidiaries or any of their respective officers, directors or employees or otherwise
in violation of the rights of any persons. The Company and its subsidiaries own or have a valid right to access and use all material computer
systems, networks, hardware, software, databases, websites, and equipment used to process, store, maintain and operate data, information,
and functions used in connection with the business of the Company and its subsidiaries (the &ldquo;<B>IT Systems</B>&rdquo;). The IT Systems
are adequate for, and operate and perform in all material respects as required in connection with, the operation of the business of the
Company and its subsidiaries as currently conducted and, to the Company&rsquo;s knowledge, are free and clear of all material bugs, errors,
defects, Trojan horses, time bombs, malware and other corruptants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(cc)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Cybersecurity;
Data Protection.</U> The Company and its subsidiaries have implemented and maintained commercially reasonable (for a company of the size
of the Company or its applicable subsidiary and operating in the industry in which the Company and its subsidiaries operate) controls,
policies, procedures, and safeguards to maintain and protect their material confidential information and the integrity, continuous operation,
redundancy and security of all IT Systems and data (including all personal, personally identifiable, sensitive, confidential or regulated
data (&ldquo;<B>Personal Data</B>&rdquo;)) used in connection with their businesses, and there have been no known breaches, violations,
outages or unauthorized uses of or accesses to same, except as would not, individually or in the aggregate, reasonably be expected to
have a Material Adverse Effect, nor any incidents under internal review or investigations relating to the same. The Company and its subsidiaries
are presently in material compliance with all applicable laws or statutes and all judgments, orders, rules&nbsp;and regulations of any
court or arbitrator or governmental or regulatory authority, internal policies and contractual obligations relating to the privacy and
security of IT Systems and Personal Data and to the protection of such IT Systems and Personal Data from unauthorized use, access, misappropriation
or modification. Neither the Company nor its subsidiaries has been notified of, and each of them has no knowledge of any event or condition
that could result in, any security breach or incident, unauthorized access or disclosure or other compromise to its IT Systems and Personal
Data, except, in each case, for any such mater as would not reasonably be expected to have a Material Adverse Effect. The Company and
its subsidiaries have implemented backup and disaster recovery technology consistent with industry standards and practice.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(dd)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Statistical
and Market-Related Data</U>. Nothing has come to the attention of the Company that has caused the Company to believe that the statistical,
industry-related and market-related data included in the Registration Statement, the Disclosure Package and the Prospectus are based on
or derived from sources that are not reliable and accurate in all material respects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ee)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Compliance
with ERISA</U>.&nbsp; Except, in each case, for any such matter as would not reasonably be expected to have a Material Adverse Effect,
(i)&nbsp;each &ldquo;employee benefit plan&rdquo; (within the meaning of Section&nbsp;3(3)&nbsp;of the Employee Retirement Income Security
Act of 1974, as amended, including the regulations and published interpretations thereunder (&ldquo;<B>ERISA</B>&rdquo;)) for which the
Company or any member of its &ldquo;<B>Controlled Group</B>&rdquo; (defined as any organization that is a member of a controlled group
of corporations within the meaning of Section&nbsp;414 of the Internal Revenue Code of 1986, as amended (the &ldquo;<B>Code</B>&rdquo;))
would have liability (each a &ldquo;<B>Plan</B>&rdquo;) is in compliance in all material respects with all applicable statutes, rules&nbsp;and
regulations, including ERISA and the Code; (ii)&nbsp;with respect to each Plan subject to Title IV of ERISA (A)&nbsp;no &ldquo;reportable
event&rdquo; (as defined in Section&nbsp;4043 of ERISA) has occurred for which the Company or any member of its Controlled Group would
have any material liability; and (B)&nbsp;neither the Company nor any member of its Controlled Group has incurred or expects to incur
material liability under Title IV of ERISA (other than for contributions to the Plan or premiums payable to the Pension Benefit Guaranty
Corporation, in each case in the ordinary course and without default); (iii)&nbsp;no Plan which is subject to Section&nbsp;412 of the
Code or Section&nbsp;302 of ERISA has failed to satisfy the minimum funding standard within the meaning of such sections of the Code or
ERISA; and (iv)&nbsp;each Plan that is intended to be qualified under Section&nbsp;401(a)&nbsp;of the Code is so qualified and nothing
has occurred, whether by action or by failure to act, which would cause the loss of such qualification.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ff)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Environmental
Laws</U>. &nbsp;Except in each case as otherwise disclosed in the Registration Statement, the Disclosure Package and the Prospectus and
except in each case as would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect: (i)&nbsp;the
Company and its subsidiaries have complied with all applicable federal, state, local, foreign and international laws (including the common
law), statutes, rules, regulations, orders, judgments, decrees or other legally binding requirements of any court, administrative agency
or other governmental authority relating to pollution or to the protection of the environment, natural resources or human health or safety,
or to the manufacture, use, generation, treatment, storage, disposal, release or threatened release of hazardous or toxic substances,
pollutants, contaminants or wastes, or the arrangement for such activities (&ldquo;<B>Environmental Laws</B>&rdquo;); (ii)&nbsp;the Company
and its subsidiaries have obtained and complied with all permits, licenses, authorizations or other approvals required of them under Environmental
Laws to conduct their respective businesses and are not subject to any action to revoke, terminate, cancel, limit or appeal any such permits,
licenses, authorizations or approvals; and (iii)&nbsp;none of the Company or any of its subsidiaries has received written notice of or
is otherwise subject to any pending or threatened claim, or has any cost or liability under Environmental Laws in respect of its past
or present business, operations (including the disposal of hazardous substances at any off-site location), facilities or real property
(whether owned, leased or operated) or on account of any predecessor or any person whose liability under any Environmental Laws it has
agreed to assume; and the Company is not aware of any facts or conditions that could reasonably be expected to give rise to any such claim,
cost or liability. Except in each case as otherwise disclosed in the Registration Statement, the Disclosure Package and the Prospectus,
none of the Company or any of its subsidiaries is aware of any facts or issues relating to compliance with Environmental Laws that would
reasonably be expected to have a material effect on their capital expenditures, earnings or competitive position or is a party to any
judicial or administrative proceeding (including a notice of violation) under any Environmental Laws to which a governmental authority
is also a party and which involves potential monetary sanctions, unless it could reasonably be expected that such proceeding will result
in monetary sanctions of less than $300,000, or which is otherwise material, and no such proceeding has, to the Company&rsquo;s knowledge,
been threatened in writing or is known by the Company to be contemplated.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(gg)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Restrictions
on Dividends</U>. Except as disclosed in the Registration Statement, the Disclosure Package and the Prospectus, <FONT STYLE="font-family: Times New Roman, Times, Serif">no
subsidiary of the Company is prohibited or restricted, directly or indirectly, from paying dividends to the Company or any other subsidiary
of the Company, or from making any other distribution with respect to such subsidiary&rsquo;s equity securities or from repaying to the
Company or any other subsidiary of the Company any amounts that may from time to time become due under any loans or advances to such subsidiary
from the Company or any other subsidiary of the Company or from transferring any property or assets to the Company or to any other subsidiary
of the Company.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(hh)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>NASDAQ
Listing</U>.&nbsp;The Company&rsquo;s Common Stock has been registered pursuant to Section&nbsp;12(b)&nbsp;of the Exchange Act, the Company&rsquo;s
outstanding shares of Common Stock have been listed, and the Shares have been approved for listing, subject to official notice of issuance,
on the NASDAQ <B>(&ldquo;NASDAQ&rdquo;)</B>, and the Company has taken no action designed to, or likely to have the effect of, terminating
the registration of the Common Stock under the Exchange Act or the listing of the Common Stock (including the Shares) on NASDAQ, nor has
the Company received any notification that the Commission or NASDAQ is contemplating terminating such registration or listing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Certain
Relationships and Related Party Transactions</U>.&nbsp; There are no material related-party transactions involving the Company or its
subsidiaries or any other person required to be described in the Registration Statement, the Disclosure Package and the Prospectus which
have not been described in such documents as required.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(jj)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Absence
of Labor Dispute</U>. No material labor disturbance by or material dispute with employees of the Company or any of its subsidiaries exists
or, to the knowledge of the Company, is threatened.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(kk)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>No
Finder&rsquo;s Fee</U>.&nbsp; None of the Company or any of its subsidiaries is a party to any contract, agreement or understanding with
any person (other than this Agreement) that would give rise to a valid claim against the Company or any of its subsidiaries or the Manager
for a brokerage commission, finder&rsquo;s fee or like payment in connection with the offering and sale of the Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ll)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Absence
of Proceedings</U>.&nbsp; Other than as set forth in the Registration Statement, the Disclosure Package and the Prospectus, there are
no legal or governmental proceedings pending to which the Company or any of its subsidiaries or, to the Company&rsquo;s knowledge, any
officer or director of the Company is a party or of which any property or assets of the Company or any of its subsidiaries is the subject
which, if determined adversely to such entity, would, individually or in the aggregate, reasonably be expected to have a Material Adverse
Effect; and, to the knowledge of the Company, no such proceedings are threatened or contemplated by governmental authorities or threatened
by others.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(mm)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Transfer
Taxes</U>.&nbsp; There are no transfer taxes or other similar fees or charges under U.S. federal law or the laws of any state, or any
political subdivision thereof, required to be paid in connection with the execution and delivery of this Agreement or the issuance or
sale by the Company of the Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(nn)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Investment
Company Act</U>. The Company is not and, upon the issuance and sale of the Shares and the application of the proceeds thereof as described
in the Registration Statement, the Disclosure Package and the Prospectus under the caption &ldquo;Use of Proceeds,&rdquo; will not be,
an &ldquo;investment company&rdquo;, as such term is defined in the Investment Company Act of 1940, as amended.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(oo)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Financial
Statements; Non-GAAP Financial Measures</U>. The financial statements, together with related notes and schedules, included in the Registration
Statement, the Disclosure Package and the Prospectus, comply in all material respects with the applicable requirements of the Act and
present fairly in all material respects the financial position and the results of operations and cash flows of the entities purported
to be shown thereby, at the indicated dates and for the indicated periods. Such financial statements and related schedules have been prepared
in accordance with GAAP, consistently applied throughout the periods involved, except as disclosed therein, and all adjustments necessary
for a fair presentation of results for such periods have been made. The pro forma financial statements, if any, or data included in the
Registration Statement or the Prospectus, if any, comply with the applicable requirements of the Act and the Exchange Act, and the assumptions
used in the preparation of such pro forma financial statements and data are reasonable, the pro forma adjustments used therein are appropriate
to give effect to the transactions or circumstances described therein and the pro forma adjustments have been properly applied to the
historical amounts in the compilation of those statements and data; the other financial and statistical data set forth in the Registration
Statement, the Disclosure Package or the Prospectus are accurately and fairly presented and prepared on a basis consistent with the financial
statements and books and records of the Company. Any non-GAAP financial measure (as such term is defined by the rules&nbsp;and regulations
of the Commission), contained in the Registration Statement, the Disclosure Package and the Prospectus has been derived from the accounting
records of the Company or its predecessors for accounting purposes, fairly presents in all material respect the information purported
to be shown thereby and complies in all material respects with Regulation G of the Exchange Act, and Item 10(e)&nbsp;of Regulation S-K
under the Act, to the extent applicable. The Company and its subsidiaries do not have any material liabilities or obligations, direct
or contingent, not disclosed in Registration Statement, the Disclosure Package and the Prospectus. There are no financial statements (historical
or pro forma) that are required to be included in the Registration Statement, the Disclosure Package or the Prospectus that are not included
as required.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(pp)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Independent
Accountants</U>. The accountants who certified the financial statements and supporting schedules included in the Registration Statement,
the Disclosure Package and the Prospectus are independent public accountants as required by the Act, the Exchange Act and the Public Company
Accounting Oversight Board.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(qq)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Compliance
with the Sarbanes-Oxley Act.</U> There is and has been no failure on the part of the Company or any of the Company&rsquo;s directors or
officers, in their capacities as such, to comply in all material respects with any applicable provision of the Sarbanes-Oxley Act of 2002
and the rules&nbsp;and regulations promulgated in connection therewith, including Section&nbsp;402 related to loans and Sections 302 and
906 related to certifications.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(rr)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Accounting
Controls</U>. The Company maintains a system of internal control over financial reporting (as such term is defined in Rule&nbsp;13a-15(f)&nbsp;under
the Exchange Act) that complies with the requirements of the Exchange Act applicable to the Company and has been designed by the Company&rsquo;s
principal executive officer and principal financial officer, or under their supervision, to provide reasonable assurance regarding the
reliability of financial reporting and the preparation of financial statements for external purposes in accordance with GAAP. The Company
is not aware of any material weaknesses in its internal control over financial reporting. Since the date of the latest audited financial
statements included or incorporated by reference in the Disclosure Package, Registration Statement and the Prospectus, there has been
no change in the Company&rsquo;s internal control over financial reporting that has materially affected, or is reasonably likely to materially
affect, the Company&rsquo;s internal control over financial reporting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ss)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Disclosure
Controls</U>. The Company maintains disclosure controls and procedures (as such term is defined in Rule&nbsp;13a-15(e)&nbsp;under the
Exchange Act) that comply with the requirements of the Exchange Act; such disclosure controls and procedures have been designed to ensure
that material information relating to the Company and its subsidiaries is made known to the Company&rsquo;s principal executive officer
and principal financial officer by others within those entities; and such disclosure controls and procedures are effective.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(tt)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Foreign
Corrupt Practices Act</U>.&nbsp; None of the Company, any of its subsidiaries or, to the knowledge of the Company, any director, officer,
employee, agent, affiliate or other person associated with or acting on behalf of the Company or any of its subsidiaries has (A)&nbsp;used
any funds for any unlawful contribution, gift, entertainment or other unlawful expense relating to political activity; (B)&nbsp;made or
taken an act in furtherance of an offer, promise or authorization of any direct or indirect unlawful payment or benefit to any foreign
or domestic government or regulatory official or employee, including of any government-owned or controlled entity or of a public international
organization, or any person acting in an official capacity for or on behalf of any of the foregoing, or any political party or party official
or candidate for political office; (C)&nbsp;violated or is in violation of any provision of the Foreign Corrupt Practices Act of 1977,
as amended, or any applicable law or regulation implementing the OECD Convention on Combating Bribery of Foreign Public Officials in International
Business Transactions, or committed an offence under the Bribery Act 2010 of the United Kingdom, or any other applicable anti-bribery
or anti-corruption laws; or (D)&nbsp;made, offered, agreed, requested or taken an act in furtherance of any unlawful bribe or other unlawful
benefit, including, without limitation, any rebate, payoff, influence payment, kickback or other unlawful or improper payment or benefit.
The Company and its subsidiaries have instituted, and maintain and enforce, policies and procedures designed to promote and ensure compliance
with all applicable anti-bribery and anti-corruption laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(uu)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Money
Laundering Laws</U>.&nbsp; The operations of the Company and its subsidiaries are and have been conducted at all times in compliance with
applicable financial recordkeeping and reporting requirements, including those of the Currency and Foreign Transactions Reporting Act
of 1970, as amended, the applicable money laundering statutes of all jurisdictions where the Company or any of its subsidiaries conducts
business, the rules&nbsp;and regulations thereunder and any related or similar rules, regulations or guidelines issued, administered or
enforced by any governmental or regulatory agency (collectively, the &ldquo;<B>Anti-Money Laundering Laws</B>&rdquo;) and no action, suit
or proceeding by or before any court or governmental or regulatory agency, authority or body or any arbitrator involving the Company or
any of its subsidiaries with respect to the Anti-Money Laundering Laws is pending or, to the knowledge of the Company, threatened.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(vv)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>OFAC</U>.&nbsp;
None of the Company, any of its subsidiaries or, to the knowledge of the Company, any director, officer, employee, agent or affiliate
of the Company is currently the subject or the target of any sanctions administered or enforced by the U.S. Government, including, without
limitation, the Office of Foreign Assets Control of the U.S. Department of the Treasury (&ldquo;<B>OFAC</B>&rdquo;), or the U.S. Department
of State and including, without limitation, the designation as a &ldquo;specially designated national&rdquo; or &ldquo;blocked person&rdquo;,
the United Nations Security Council (&ldquo;<B>UNSC</B>&rdquo;), the European Union, Her Majesty&rsquo;s Treasury (&ldquo;<B>HMT</B>&rdquo;),
or other relevant sanctions authority (collectively, &ldquo;<B>Sanctions</B>&rdquo;), nor is the Company or any of its subsidiaries located,
organized or resident in a country or territory that is the subject or the target of Sanctions (each, a &ldquo;<B>Sanctioned Country</B>&rdquo;);
and the Company will not directly or indirectly use the proceeds of the offering of the Shares hereunder, or lend, contribute or otherwise
make available such proceeds to any subsidiary, joint venture partner or other person or entity (i)&nbsp;to fund or facilitate any activities
of or business with any person that, at the time of such funding or facilitation, is the subject or the target of Sanctions, (ii)&nbsp;to
fund or facilitate any activities of or business in any Sanctioned Country or (iii)&nbsp;in any other manner that will result in a violation
by any person (including any person participating in the transaction, whether as sales agent, underwriter, advisor, investor or otherwise)
of Sanctions. For the past five years, none of the Company or any of its subsidiaries has knowingly engaged in and are not now knowingly
engaged in any dealings or transactions with any person that at the time of the dealing or transaction is or was the subject or the target
of Sanctions or with any Sanctioned Country.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ww)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Insurance</U>.
Each of the Company and its subsidiaries carry, or are covered by, insurance, from financially sound and reputable insurers, in such amounts
and covering such risks as are generally deemed reasonably adequate for the conduct of their respective businesses and the value of their
respective properties and as is generally deemed adequate and customary for companies engaged in similar businesses; and the Company has
no reason to believe that it or any of its subsidiaries will not be able to renew their existing insurance coverage as and when such coverage
expires or to obtain similar coverage from similar insurers as may be necessary to continue their respective businesses at a cost that
would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xx)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Stabilization</U>.&nbsp;
Neither the Company nor, to the Company&rsquo;s knowledge, any of its affiliates, has taken or may take, directly or indirectly, any action
designed to cause or result in, or which has constituted or which might reasonably be expected to constitute, the stabilization or manipulation
of the price of any security of the Company to facilitate the sale or resale of the Shares in violation of Regulation M of the Exchange
Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(yy)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>FINRA
Affiliation</U>.&nbsp; To the knowledge of the Company, there are no affiliations or associations between any member of FINRA and any
of the officers or directors of the Company or the holders of 10% or greater of the Common Stock, except as described in the Registration
Statement, the Disclosure Package and the Prospectus to the extent required to be described.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(zz)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Accuracy
of Exhibits</U>. There are no contracts or other documents that are required by the Act to be described in the Prospectus or filed as
exhibits to the Registration Statement, or that are required by the Exchange Act to be filed as exhibits to a document incorporated by
reference into the Prospectus, that have not been so described in the Prospectus or filed as exhibits to the Registration Statement or
such incorporated document.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(aaa)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>XBRL</U>.
The interactive data in the eXtensible Business Reporting Language included as an exhibit to the Registration Statement fairly presents
the information called for in all material respects and has been prepared in accordance with the Commission&rsquo;s rules&nbsp;and guidelines
applicable thereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(bbb)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>WKSI</U>.
(i)&nbsp;At the original effectiveness of the Registration Statement, (ii)&nbsp;at the time of the most recent amendment thereto for the
purposes of complying with Section&nbsp;10(a)(3)&nbsp;of the Act (whether such amendment was by post-effective amendment or incorporated
report filed pursuant to Section&nbsp;13 or 15(d)&nbsp;of the Exchange Act or in the form of a prospectus), (iii)&nbsp;at the time the
Company or any person acting on its behalf (within the meaning, for this clause only, of Rule&nbsp;163(c)) made any offer relating to
the Shares in reliance on the exemption of Rule&nbsp;163, and (iv)&nbsp;as of the Applicable Time, the Company was and is a &ldquo;well-known
seasoned issuer&rdquo; (as defined in Rule&nbsp;405 of the Act).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any certificate signed by
any officer of the Company or any of its subsidiaries and delivered to the Manager or to counsel for the Manager in connection with this
Agreement or any Terms Agreement shall be deemed a representation and warranty by the Company or such subsidiary of the Company, as applicable,
to the Manager as to the matters set forth therein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company acknowledges that
the Manager and, for purposes of the opinions to be delivered pursuant to Section&nbsp;4 hereof, counsel for the Company and counsel for
the Manager, will rely upon the accuracy and truthfulness of the foregoing representations and hereby consents to such reliance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Sale
and Delivery of Shares</U>. On the basis of the representations, warranties and agreements herein contained, but subject to the terms
and conditions herein set forth, the Company and the Manager agree that the Company may from time to time seek to sell Shares through
the Manager, acting as sales agent, or directly to the Manager acting as principal, as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">The
Company may submit to the Manager its orders (including any price, time or size limits or other customary parameters or conditions) to
sell Shares on any Trading Day (as defined herein) in a form and manner as mutually agreed to by the Company and the Manager. As used
herein, &ldquo;<B>Trading Day</B>&rdquo; shall mean any trading day on the NASDAQ.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Subject
to the terms and conditions hereof, the Manager shall use its reasonable efforts to execute any Company order submitted to it hereunder
to sell Shares and with respect to which the Manager has agreed to act as sales agent. The Company acknowledges and agrees that (i)&nbsp;there
can be no assurance that the Manager will be successful in selling the Shares, (ii)&nbsp;the Manager will incur no liability or obligation
to the Company or any other person or entity if it does not sell Shares for any reason other than a failure by the Manager to use its
reasonable efforts consistent with its normal trading and sales practices and applicable law and regulations to sell such Shares as required
under this Agreement and (iii)&nbsp;the Manager shall not be under any obligation to purchase Shares on a principal basis pursuant to
this Agreement, except as otherwise specifically agreed by the Manager and the Company. The Manager may make sales pursuant to each order
by any method permitted by law, including without limitation (i)&nbsp;by means of ordinary brokers&rsquo; transactions (whether or not
solicited), (ii)&nbsp;to or through a market maker, (iii)&nbsp;directly on or through any national securities exchange or facility thereof,
a trading facility of a national securities association, an alternative trading system, or any other market venue, (iv)&nbsp;in the over-the-counter
market, (v)&nbsp;in privately negotiated transactions, or (vi)&nbsp;through a combination of any such methods.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">The
Company shall not authorize the issuance and sale of, and the Manager shall not sell as sales agent, any Share at a price lower than the
minimum price therefor designated from time to time by the Company and notified to the Manager in writing. In addition, the Company or
the Manager may upon notice to the other party hereto by telephone (confirmed promptly by email or facsimile), suspend an offering of
the Shares with respect to which the Manager is acting as sales agent; <I>provided</I>, <I>however</I>, that such suspension or termination
shall not affect or impair the parties&rsquo; respective obligations with respect to the Shares sold hereunder prior to the giving of
such notice.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">The
compensation to the Manager for sales of the Shares with respect to which the Manager acts as sales agent hereunder shall be up to 3.0%
of the gross offering proceeds of the Shares sold pursuant to this Agreement as mutually agreed to in writing by the Manager and the Company.
The foregoing rate of compensation shall not apply when the Manager, acting as principal, purchases Shares from the Company pursuant to
a Terms Agreement. Any compensation or commission due and payable to the Manager hereunder with respect to any sale of Shares shall be
paid by the Company to the Manager concurrently with the settlement for sales of the Shares by deduction from the proceeds from sales
of the Shares payable to the Company. The remaining proceeds, after further deduction for any transaction fees imposed by any governmental
or self-regulatory organization in respect of such sales shall constitute the net proceeds to the Company for such Shares (the &ldquo;<B>Net
Proceeds</B>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Settlement
for sales of the Shares pursuant to this Agreement will occur on the second Trading Day following the date on which such sales are made
(each such day, a &ldquo;<B>Settlement Date</B>&rdquo;). On each Settlement Date, the Shares sold through the Manager for settlement on
such date shall be issued and delivered by the Company to the Manager against payment of the Net Proceeds from the sale of such Shares.
Settlement for all such Shares shall be effected by free delivery of the Shares, in definitive form, by the Company or its transfer agent
to the Manager&rsquo;s or its designee&rsquo;s account (<I>provided</I> the Manager shall have given the Company written notice of such
designee prior to the Settlement Date) at The Depository Trust Company through its Deposit and Withdrawal at Custodian System or by such
other means of delivery as may be mutually agreed upon by the parties hereto, in return for payments in same day funds delivered to the
account designated by the Company. If the Company, or its transfer agent (if applicable) shall default on its obligation to deliver the
Shares on any Settlement Date, the Company shall (i)&nbsp;hold the Manager harmless against any loss, claim, damage, or expense (including
reasonable legal fees and expenses), as incurred, arising out of or in connection with such default by the Company and (ii)&nbsp;pay the
Manager any commission, discount or other compensation to which it would otherwise be entitled absent such default.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 18; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">If
acting as sales agent hereunder, the Manager shall provide written confirmation (which may be by facsimile or email) to the Company following
the close of trading on the NASDAQ each day in which the Shares are sold under this Agreement setting forth (i)&nbsp;the amount of the
Shares sold on such day and the gross offering proceeds received from such sale and (ii)&nbsp;the commission payable by the Company to
the Manager with respect to such sales.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">At
each Applicable Time, Settlement Date, Representation Date (as defined in Section&nbsp;4(k)) and Filing Date (as defined in Section&nbsp;4(r)),
the Company shall be deemed to have affirmed each representation and warranty contained in this Agreement as if such representation and
warranty were made as of such date, modified as necessary to relate to the Registration Statement and the Prospectus as amended as of
such date. Any obligation of the Manager to use its reasonable efforts to sell the Shares on behalf of the Company as sales agent shall
be subject to the continuing accuracy of the representations and warranties of the Company herein (and the completion of any diligence
to verify such accuracy by the Manager), to the performance by the Company of its obligations hereunder and to the continuing satisfaction
of the additional conditions specified in Section&nbsp;6 of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Subject
to such further limitations on offers and sales of Shares or delivery of instructions to offer and sell Shares as are set forth herein
and as may be mutually agreed upon by the Company and the Manager, the Company shall not request the sale of any Shares that would be
sold, and the Manager shall not be obligated to sell, (i)&nbsp;during any period in which the Company&rsquo;s insider trading policy,
as it exists on the date of this Agreement, would prohibit the purchase or sale of any Shares by any of its officers or directors, (ii)&nbsp;any
time during the period commencing on the tenth business day prior to the time Company shall issue a press release containing, or shall
otherwise publicly announce, its earnings, revenues or other results of operations (each, an &ldquo;<B>Earnings Announcement</B>&rdquo;)
through and including the time that is 24 hours after the time that the Company files (a &ldquo;<B>Filing Time</B>&rdquo;) a Quarterly
Report on Form&nbsp;10-Q or an Annual Report on Form&nbsp;10-K that includes consolidated financial statements as of and for the same
period or periods, as the case may be, covered by such Earnings Announcement, or (iii)&nbsp;during any other period in which the Company
is, or could be deemed to be, in possession of material non-public information.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">If
the Company wishes to issue and sell the Shares pursuant to this Agreement directly to the Manager acting as principal (each, a &ldquo;<B>Placement</B>&rdquo;),
it will notify the Manager of the proposed terms of such Placement. If the Manager, acting as principal, wishes to accept such proposed
terms (which Manager may decline to do for any reason in its sole discretion) or, wishes to accept amended terms proposed by the Company
after further discussion, the Manager and the Company will enter into a Terms Agreement setting forth the terms of such Placement. The
terms set forth in a Terms Agreement will not be binding on the Company or the Manager unless and until the Company and the Manager have
each executed such Terms Agreement accepting all of the terms of such Terms Agreement. In the event of a conflict between the terms of
this Agreement and the terms of a Terms Agreement, the terms of such Terms Agreement will control.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 19; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(j)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Each
Placement shall be made in accordance with the terms of this Agreement and, if applicable, a Terms Agreement, which will provide for the
sale of such Shares to, and the purchase thereof by, the Manager. A Terms Agreement may also specify certain provisions relating to the
reoffering of such Shares by the Manager. The commitment of the Manager to purchase the Shares pursuant to any Terms Agreement shall be
deemed to have been made on the basis of the representations and warranties of the Company herein contained and shall be subject to the
terms and conditions herein set forth. Each Terms Agreement shall specify the number of the Shares to be purchased by the Manager pursuant
thereto, the price to be paid to the Company for such Shares, any provisions relating to rights of, and default by, underwriters acting
together with the Manager in the reoffering of the Shares, and the time and date (each such time and date being referred to herein as
a &ldquo;<B>Time of Delivery</B>&rdquo;) and place of delivery of and payment for such Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(k)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Under
no circumstances shall the number and aggregate amount of the Shares sold pursuant to this Agreement and any Terms Agreement exceed (i)&nbsp;the
aggregate amount set forth in Section&nbsp;1, (ii)&nbsp;the number of shares of the Common Stock available for issuance under the currently
effective Registration Statement or (iii)&nbsp;the number and aggregate amount of the Shares authorized from time to time to be issued
and sold under this Agreement by the board of directors of the Company (the &ldquo;<B>Board</B>&rdquo;), or a duly authorized committee
thereof, and notified to the Manager in writing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Agreements</U>.
The Company agrees with the Manager that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">During
any period when the delivery of a prospectus relating to the Shares is required (including in circumstances where such requirement may
be satisfied pursuant to Rule&nbsp;172 or any similar rule) to be delivered under the Act in connection with the offering or sale of the
Shares, the Company will not file any amendment of the Registration Statement or supplement in connection with the offering and sale of
the Shares (including the Prospectus Supplement or any Interim Prospectus Supplement) to the Base Prospectus, the Disclosure Package or
the Prospectus, whether pursuant to the Act, the Exchange Act or otherwise, unless (i)&nbsp;the Company has furnished to the Manager a
copy of such amendment or supplement (including, for the avoidance of doubt, reports or other information to be filed by the Company under
the Exchange Act that would be incorporated by reference into the Registration Statement and the Prospectus) for its review a reasonable
period of time prior to filing (or, in the case of Current Reports on Form&nbsp;8-K, has used its commercially reasonable efforts to so
furnish copies to the Manager prior to filing), and (ii)&nbsp;except for reports or other information required to be filed by the Company
under the Exchange Act, the Company will not file any such proposed amendment or supplement to which the Manager reasonably objects. The
Company has prepared the Prospectus, in a form approved by the Manager, and shall file such Prospectus, as amended at the Execution Time,
with the Commission pursuant to the applicable paragraph of Rule&nbsp;424(b)&nbsp;promptly after the Execution Time (but in any event
within the time period described thereby) and will cause any supplement to the Prospectus to be prepared, in a form approved by the Manager,
and will file such supplement with the Commission pursuant to the applicable paragraph of Rule&nbsp;424(b)&nbsp;within the time period
prescribed thereby and will notify the Manager of such timely filing. The Company, subject to this Section&nbsp;4(a)&nbsp;and Section&nbsp;4(c),
will comply with the requirements of Rule&nbsp;430B. During any period when the delivery of a prospectus relating to the Shares is required
(including in circumstances where such requirement may be satisfied pursuant to Rule&nbsp;172 or any similar rule) to be delivered under
the Act in connection with the offering or sale of the Shares, the Company will promptly advise the Manager (A)&nbsp;when the Prospectus,
and any supplement thereto, shall have been filed (if required) with the Commission pursuant to Rule&nbsp;424(b), (B)&nbsp;when, during
any period when the delivery of a prospectus (whether physically or through compliance with Rule&nbsp;172 or any similar rule) is required
under the Act in connection with the offering or sale of the Shares, any amendment to the Registration Statement or any new registration
statement relating to the Shares shall have been filed or become effective (other than a prospectus supplement relating solely to the
offering of securities other than the Shares), (C)&nbsp;of the receipt of any comments from the Commission, (D)&nbsp;of any request by
the Commission or its staff for any amendment of the Registration Statement, or for any supplement to the Prospectus or for any additional
information, (E)&nbsp;of the issuance by the Commission of any stop order suspending the effectiveness of the Registration Statement or
of any notice objecting to its use or any the issuance of any order preventing or suspending the use of the Prospectus or any amendment
or supplement thereto, or the institution or threatening of any proceeding for any of such purposes or pursuant to Section&nbsp;8A of
the Act or (F)&nbsp;of the receipt by the Company of any notification with respect to the suspension of the qualification of the Shares
for sale in any jurisdiction or the institution or threatening of any proceeding for such purpose. The Company will use its reasonable
best efforts to prevent the issuance of any such stop order or the occurrence of any such suspension or objection to the use of the Registration
Statement and, upon such issuance, occurrence or notice of objection, to obtain at the earliest possible moment the withdrawal of such
stop order or relief from such occurrence or objection, including, if necessary, by filing an amendment to the Registration Statement
or a new registration statement and using its reasonable best efforts to have such amendment or new registration statement declared effective
as soon as practicable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 20; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">If,
at any time on or after an Applicable Time but prior to the related Settlement Date or Time of Delivery, any event occurs as a result
of which the Disclosure Package would include any untrue statement of a material fact or omit to state any material fact necessary to
make the statements therein in the light of the circumstances under which they were made or the circumstances then prevailing not misleading,
the Company will (i)&nbsp;notify promptly the Manager so that any use of the Disclosure Package may cease until it is amended or supplemented;
(ii)&nbsp;amend or supplement the Disclosure Package to correct such statement or omission; and (iii)&nbsp;supply any amendment or supplement
to the Manager in such quantities as the Manager may reasonably request.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">During
any period when the delivery of a prospectus relating to the Shares is required (including in circumstances where such requirement may
be satisfied pursuant to Rule&nbsp;172 or any similar rule) to be delivered under the Act, if any event occurs as a result of which the
Prospectus as then supplemented would include any untrue statement of a material fact or omit to state any material fact necessary to
make the statements therein in the light of the circumstances under which they were made at such time not misleading, or if it shall be
necessary to amend the Registration Statement, file a new registration statement or supplement the Prospectus to comply with the Act or
the Exchange Act or the respective rules&nbsp;thereunder, including in connection with use or delivery of the Prospectus, the Company
promptly will (i)&nbsp;notify the Manager of any such event, (ii)&nbsp;prepare and file with the Commission, subject to the first sentence
of paragraph (a)&nbsp;of this Section&nbsp;4, an amendment or supplement or new registration statement which will correct such statement
or omission or effect such compliance, (iii)&nbsp;use its reasonable best efforts to have any amendment to the Registration Statement
or new registration statement declared effective as soon as practicable in order to avoid any disruption in use of the Prospectus and
(iv)&nbsp;supply any supplemented Prospectus to the Manager in such quantities as the Manager may reasonably request.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 21; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">As
soon as practicable, the Company will make generally available to its security holders and to the Manager an earnings statement or statements
of the Company and its subsidiaries which will satisfy the provisions of Section&nbsp;11(a)&nbsp;of the Act and Rule&nbsp;158.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">The
Company will deliver to the Manager and counsel for the Manager, without charge, as the Manager or counsel for the Manager may reasonably
request, signed copies of the Registration Statement as originally filed and of each amendment thereto (including exhibits filed therewith
or incorporated by reference therein and documents incorporated or deemed to be incorporated by reference therein) and signed copies of
all consents and certificates of experts. The Registration Statement and each amendment thereto furnished to the Manager will be identical
to any electronically transmitted copies thereof filed with the Commission pursuant to EDGAR, except to the extent permitted by Regulation
S-T. The Company will pay the expenses of printing or other production of all documents relating to the offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">The
Company will deliver to the Manager and counsel for the Manager, without charge, for so long as delivery of a prospectus by the Manager
or dealer may be required by the Act (including in circumstances where such requirement may be satisfied pursuant to Rule&nbsp;172 or
any similar rule), as many copies of the Prospectus and each Issuer Free Writing Prospectus and any supplement thereto as the Manager
may reasonably request. The Prospectus and any Issuer Free Writing Prospectus and any amendments or supplements thereto furnished to the
Manager will be identical to any electronically transmitted copies thereof filed with the Commission pursuant to EDGAR, except to the
extent permitted by Regulation S-T. The Company will pay the expenses of printing or other production of all documents relating to the
offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">The
Company will arrange, if necessary, for the qualification of the Shares for sale under the laws of such jurisdictions as the Manager may
designate and will maintain such qualifications in effect so long as required for the distribution of the Shares; <I>provided</I> that
in no event shall the Company be obligated to qualify to do business in any jurisdiction where it is not now so qualified or to take any
action that would subject it to service of process in suits, other than those arising out of the offering or sale of the Shares, in any
jurisdiction where it is not now so subject or where it would be subject to taxation as a foreign business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">The
Company agrees that, unless it has or shall have obtained the prior written consent of the Manager, and the Manager agrees with the Company
that, unless it has or shall have obtained, as the case may be, the prior written consent of the Company, it has not made and will not
make any offer relating to the Shares that would constitute an Issuer Free Writing Prospectus or that would otherwise constitute a &ldquo;free
writing prospectus&rdquo; (as defined in Rule&nbsp;405) required to be filed by the Company with the Commission or retained by the Company
under Rule&nbsp;433; <I>provided</I> that the prior written consent of the parties hereto shall be deemed to have been given in respect
of the Free Writing Prospectuses included in Schedule I hereto. Any such free writing prospectus consented to by the Manager or the Company
is hereinafter referred to as a &ldquo;<B>Permitted Free Writing Prospectus</B>.&rdquo; The Company agrees that (i)&nbsp;it has treated
and will treat, as the case may be, each Permitted Free Writing Prospectus as an Issuer Free Writing Prospectus and (ii)&nbsp;it has complied
and will comply, as the case may be, with the requirements of Rules&nbsp;164 and 433 applicable to any Permitted Free Writing Prospectus,
including in respect of timely filing with the Commission, legending and record keeping.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 22; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">The
Company will not (i)&nbsp;take, directly or indirectly, any action designed to or that might reasonably be expected to cause or result
in stabilization or manipulation of the price of any security of the Company to facilitate the sale or resale of the Shares or (ii)&nbsp;sell,
bid for, purchase or pay any person (other than as contemplated by this Agreement or any Terms Agreement) any compensation for soliciting
purchases of the Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(j)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">The
Company will, at any time during the term of this Agreement, as supplemented from time to time, advise the Manager promptly after it shall
have received notice or obtain knowledge thereof, of any information or fact that would materially alter or affect any opinion, certificate,
letter and other document provided to the Manager pursuant to Section&nbsp;6 herein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(k)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Upon
commencement of the offering of the Shares under this Agreement (if requested by the Manager) (and upon the recommencement of the offering
of the Shares under this Agreement following the termination of a suspension of sales hereunder), and each time that (i)&nbsp;the Registration
Statement or the Prospectus shall be amended or supplemented (other than (A)&nbsp;an Interim Prospectus Supplement filed pursuant to Rule&nbsp;424(b)&nbsp;pursuant
to Section&nbsp;4(q)&nbsp;of this Agreement, (B)&nbsp;a prospectus supplement relating solely to the offering or resale of securities
other than the Shares or (C)&nbsp;the filing with the Commission of any report under the Exchange Act except such reports referred to
in Section&nbsp;4(k)(ii)), (ii)&nbsp;there is filed with the Commission any annual report on Form&nbsp;10-K or quarterly report on Form&nbsp;10-Q,
or any other document that contains financial statements or financial information that is incorporated by reference into the Prospectus,
or any amendment thereto, or (iii)&nbsp;the Shares are delivered to the Manager as principal at the Time of Delivery pursuant to a Terms
Agreement (the date of such commencement (in the case that the above-mentioned request is made by the Manager), the date of each such
recommencement and the date of each such event referred to in (i), (ii)&nbsp;and (iii)&nbsp;above, a &ldquo;<B>Representation Date</B>&rdquo;),
the Company shall furnish or cause to be furnished to the Manager forthwith a certificate dated and delivered on such Representation Date,
as the case may be, in form satisfactory to the Manager to the effect that the statements contained in the certificate referred to in
Section&nbsp;6(d)&nbsp;of this Agreement which were last furnished to the Manager are true and correct at the time of such Representation
Date, as though made at and as of such time (except that such statements shall be deemed to relate to the Registration Statement and the
Prospectus as amended and supplemented to such time) or, in lieu of such certificate, a certificate of the same tenor as the certificate
referred to in said Section&nbsp;6(d), modified as necessary to relate to the Registration Statement, the Disclosure Package and the Prospectus
as amended and supplemented to the time of delivery of such certificate. The requirement to provide a certificate under this Section&nbsp;4(k)&nbsp;shall
be waived for any Representation Date occurring at a time when no Company order submitted to the Manager hereunder to sell Shares is pending
or a suspension of sales hereunder is in effect, which waiver shall continue until the earlier to occur of the date the Company submits
an order to the Manager to sell Shares hereunder (which for such calendar quarter shall be considered a Representation Date) and the next
occurring Representation Date. Notwithstanding the foregoing, if the Company subsequently decides to sell Shares following a Representation
Date when the Company relied upon the foregoing waiver and therefore did not provide the Managers with a certificate under this Section&nbsp;4(k),
then before the Company submits an order for the sale of Shares or the Manager sells any Shares pursuant to such order, the Company shall
provide the Manager with a certificate in conformity with this Section&nbsp;4(k)&nbsp;dated as of the date that the order for the sale
of Shares is submitted to the Manager hereunder, provided that for the avoidance of doubt, such date the certificate is delivered pursuant
to the foregoing sentence shall also be a Representation Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 23; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(l)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">At
each Representation Date with respect to which the Company is obligated to deliver a certificate pursuant to Section&nbsp;4(k)&nbsp;for
which no waiver is applicable, the Company shall furnish or cause to be furnished forthwith to the Manager and to counsel to the Manager
a written opinion of Troutman Pepper Hamilton Sanders LLP, counsel to the Company (&ldquo;<B>Company Counsel</B>&rdquo;), or other counsel
reasonably satisfactory to the Manager and a written opinion of Servilla Whitney LLC intellectual property counsel for the Company, each
dated and delivered on such Representation Date, in form and substance satisfactory to the Manager, of the same tenor as the opinion referred
to in Section&nbsp;6(b)&nbsp;of this Agreement, but modified as necessary to relate to the Registration Statement, the Disclosure Package
and the Prospectus as amended and supplemented to the time of delivery of such opinion.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(m)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">At
each Representation Date with respect to which the Company is obligated to deliver a certificate pursuant to Section&nbsp;4(k)&nbsp;for
which no waiver is applicable, Latham&nbsp;&amp; Watkins LLP, counsel to the Manager, shall deliver a written opinion and disclosure letter,
dated and delivered on such Representation Date, in form and substance satisfactory to the Manager, of the same tenor as the opinions
and disclosure letter referred to in Section&nbsp;6(c)&nbsp;of this Agreement but modified as necessary to relate to the Registration
Statement, the Disclosure Package and the Prospectus as amended and supplemented to the time of delivery of such opinion.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(n)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">At
each Representation Date with respect to which the Company is obligated to deliver a certificate pursuant to Section&nbsp;4(k)&nbsp;for
which no waiver is applicable, the Company shall cause Ernst&nbsp;&amp; Young LLP (the &ldquo;<B>Accountants</B>&rdquo;), or other independent
accountants satisfactory to the Manager forthwith, to furnish the Manager a letter, dated and delivered on such Representation Date, in
form and substance satisfactory to the Manager of the same tenor as the letter referred to in Section&nbsp;6(e)&nbsp;of this Agreement
but modified to relate to the Registration Statement, the Disclosure Package and the Prospectus, as amended and supplemented to the date
of such letter.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(o)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">At
each Representation Date with respect to which the Company is obligated to deliver a certificate pursuant to Section&nbsp;4(k)&nbsp;for
which no waiver is applicable, if requested by the Manager, the Company shall furnish to the Manager, dated and delivered on such Representation
Date, in form and substance satisfactory to the Manager, of its Chief Financial Officer with respect to certain financial data contained
in the Prospectus, providing &ldquo;management comfort&rdquo; with respect to such information.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 24; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(p)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">At
each Representation Date, and at such other times as may be reasonably requested by the Manager (which shall be on a monthly basis or
otherwise), the Company will conduct a due diligence session, in form and substance satisfactory to the Manager, which shall include representatives
of the management of the Company and the independent accountants of the Company. The Company shall cooperate timely with any reasonable
due diligence request from or review conducted by the Manager or its agents from time to time in connection with the transactions contemplated
by this Agreement, including, without limitation, providing information and available documents and access to appropriate officers and
agents of the Company during regular business hours and at the Company&rsquo;s principal offices, and timely furnishing or causing to
be furnished such certificates, letters and opinions from the Company, and their officers and agents, as the Manager may reasonably request.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(q)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Nothing
in this Agreement shall restrict the Manager from trading, and the Company acknowledges that the Manager may trade in the Common Stock
for the Manager&rsquo;s own account and for the account of its clients before, at the same time as, or after sales of the Shares occur
pursuant to this Agreement or pursuant to a Terms Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(r)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">The
Company will either (i)&nbsp;disclose in its Annual Reports on Form&nbsp;10-K and Quarterly Reports on Form&nbsp;10-Q, as applicable,
with regard to the relevant quarter, the number of the Shares sold by or through the Manager pursuant to this Agreement, the Net Proceeds
to the Company and the compensation paid by the Company with respect to such sales of the Shares pursuant to this Agreement, or (ii)&nbsp;on
or prior to the earlier of (A)&nbsp;the date on which the Company shall file a Quarterly Report on Form&nbsp;10-Q or an Annual Report
on Form&nbsp;10-K in respect of any fiscal quarter in which sales of Shares were made by the Manager pursuant to this Agreement and (B)&nbsp;the
date on which the Company shall be obligated to file such document referred to in clause (A)&nbsp;in respect of such quarter (each such
date, and any date on which an amendment to any such document is filed, a &ldquo;<B>Filing Date</B>&rdquo;), the Company will file a prospectus
supplement with the Commission under the applicable paragraph of Rule&nbsp;424(b), which prospectus supplement will set forth, with regard
to such quarter, the number of the Shares sold by or through the Manager pursuant to this Agreement, the Net Proceeds to the Company and
the compensation paid by the Company with respect to such sales of the Shares pursuant to this Agreement and deliver such number of copies
of each such prospectus supplement to the NASDAQ as are required by such exchange.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(s)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">If,
to the knowledge of the Company, the conditions set forth in Section&nbsp;6(a)&nbsp;or 6(f)&nbsp;shall not be true and correct on the
applicable Settlement Date or Time of Delivery, the Company will offer to any person who has agreed to purchase Shares from the Company
as the result of an offer to purchase solicited by the Manager the right to refuse to purchase and pay for such Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(t)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Each
acceptance by the Company of an offer to purchase the Shares hereunder, and each execution and delivery by the Company of a Terms Agreement,
shall be deemed to be an affirmation to the Manager, or the Manager party to a Terms Agreement, as the case may be, that the representations
and warranties of the Company contained in or made pursuant to this Agreement are true and correct as of the date of such acceptance or
of such Terms Agreement as though made at and as of such date, and an undertaking that such representations and warranties will be true
and correct as of the Settlement Date for the Shares relating to such acceptance or as of the Time of Delivery relating to such sale,
as the case may be, as though made at and as of such date (except that such representations and warranties shall be deemed to relate to
the Registration Statement and the Prospectus as amended and supplemented relating to such Shares).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 25; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(u)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">The
Company will use its commercially reasonable efforts to cause the Shares to be listed for trading on NASDAQ and to maintain such listing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">During
any period when the delivery of a prospectus relating to the Shares is required (including in circumstances where such requirement may
be satisfied pursuant to Rule&nbsp;172 or any similar rule) to be delivered under the Act, the Company shall file, on a timely basis,
with the Commission and the NASDAQ all reports and documents required to be filed under the Exchange Act and the regulations thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(w)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">The
Company shall cooperate with the Manager and use its reasonable efforts to permit the Shares to be eligible for clearance and settlement
through the facilities of DTC.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(x)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">The
Company will apply the Net Proceeds from the sale of the Shares in the manner set forth in the Disclosure Package and the Prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Payment
of Expenses</U>. The Company agrees to pay all reasonable costs, fees and expenses incurred in connection with the performance of its
obligations under this Agreement, whether or not the transactions contemplated hereby are consummated, including without limitation (i)&nbsp;all
expenses incident to the issuance and delivery of the Shares (including all printing and engraving costs), (ii)&nbsp;all necessary issue,
transfer and other stamp taxes in connection with the issuance and sale of the Shares, (iii)&nbsp;all reasonable fees and expenses of
the Company&rsquo;s counsel, independent public or certified public accountants and other advisors to the Company, and the reasonable
fees and expenses of the Manager&rsquo;s counsel (which shall be one outside counsel for the Manager unless otherwise agreed by the Company)
(iv)&nbsp;all costs and expenses incurred in connection with the preparation, printing, filing, shipping and distribution of the Registration
Statement (including financial statements, exhibits, schedules, consents and certificates of experts), each Issuer Free Writing Prospectus
and the Prospectus, and all amendments and supplements thereto, and this Agreement, (v)&nbsp;all filing fees, reasonable attorneys&rsquo;
fees and expenses incurred by the Company or the Manager in connection with qualifying or registering (or obtaining exemptions from the
qualification or registration of) all or any part of the Shares for offer and sale under the state securities or blue sky laws, and, if
requested by the Manager, preparing a &ldquo;Blue Sky Survey&rdquo; or memorandum, and any supplements thereto, advising the Manager of
such qualifications, registrations and exemptions, (vi)&nbsp;the filing fees incident to the review and approval by FINRA of the terms
of the sale of the Shares, (vii)&nbsp;the fees and expenses associated with listing of the Shares on the NASDAQ, (viii)&nbsp;all fees
and expenses of the registrar and transfer agent of the Common Stock, (ix)&nbsp;all fees and expenses (including reasonable fees and expenses
of counsel) of the Company in connection with approval of the Shares by DTC for &ldquo;book-entry&rdquo; transfer, (x)&nbsp;all other
fees, costs and expenses referred to in Item 14 of Part&nbsp;II of the Registration Statement and (xi)&nbsp;all other fees, costs and
expenses incurred in connection with the performance of its obligations hereunder for which provision is not otherwise made in this Section&nbsp;5;
provided, however, that the amount payable by the Company pursuant to subsection (iii)&nbsp;with respect to the reasonable fees and expenses
of Manager&rsquo;s counsel shall not exceed (A)&nbsp;$250,000 arising out of the executing this Agreement and the filing of the Registration
Statement and the Prospectus and (B)&nbsp;in the amount not to exceed $25,000 per each quarter thereafter (solely for any quarter that
includes a Representation Date with respect to which the Company is obligated to deliver a certificate pursuant to Section&nbsp;4(k)&nbsp;for
which no waiver is applicable). Except as provided in this Section&nbsp;5 and in Section&nbsp;7 hereof, the Manager shall pay their own
expenses.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 26; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Conditions
to the Obligations of the Manager</U>. The obligations of the Manager under this Agreement and any Terms Agreement shall be subject to
(i)&nbsp;the accuracy of the representations and warranties on the part of the Company contained herein as of the Execution Time, each
Representation Date, and as of each Applicable Time, Settlement Date and Time of Delivery, (ii)&nbsp;to the performance by the Company
of its obligations hereunder and (iii)&nbsp;the following additional conditions:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">The
Prospectus, and any supplement thereto, required by Rule&nbsp;424 to be filed with the Commission have been filed in the manner and within
the time period required by Rule&nbsp;424(b)&nbsp;with respect to any sale of Shares; each Interim Prospectus Supplement shall have been
filed in the manner required by Rule&nbsp;424(b)&nbsp;within the time period required by Section&nbsp;4(q)&nbsp;of this Agreement; any
material required to be filed by the Company pursuant to Rule&nbsp;433(d)&nbsp;under the Act, shall have been filed with the Commission
within the applicable time periods prescribed for such filings by Rule&nbsp;433; and no stop order suspending the effectiveness of the
Registration Statement or any notice objecting to its use shall have been issued and no proceedings for that purpose or pursuant to Section&nbsp;8A
of the Act shall have been instituted or threatened.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">The
Company shall have requested and caused Company Counsel and Intellectual Property Counsel to furnish to the Manager, on every date specified
in Section&nbsp;4(l)&nbsp;of this Agreement, opinions in form and substance satisfactory to the Manager.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">The
Manager shall have received from Latham&nbsp;&amp; Watkins LLP, counsel for the Manager, on every date specified in Section&nbsp;4(m)&nbsp;of
this Agreement, such opinion or opinions and disclosure letter or letters, dated as of such date and addressed to the Manager, with respect
to the issuance and sale of the Shares, the Registration Statement, the Disclosure Package, the Prospectus (together with any supplement
thereto) and other related matters as the Manager may reasonably require, and the Company shall have furnished to such counsel such documents
as they reasonably request for the purpose of enabling them to pass upon such matters.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">The
Company shall have furnished or caused to be furnished to the Manager, on every date specified in Section&nbsp;4(k)&nbsp;of this Agreement,
a certificate of the Company, signed by the chief executive officer or the President of the Company, and of the chief financial or chief
accounting officer of the Company, dated as of such date, to the effect that the signers of such certificate have carefully examined the
Registration Statement, the Disclosure Package and the Prospectus and any supplements or amendments thereto and this Agreement and that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">the
Company has received no stop order suspending the effectiveness of the Registration Statement, and no proceedings for such purpose or
pursuant to Section&nbsp;8A of the Act have been instituted or, to the Company&rsquo;s knowledge, threatened by the Commission;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 27; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">since
the date of the most recent financial statements included in the Prospectus and the Disclosure Package, there has been no event or condition
of a type described in Section&nbsp;2(l)&nbsp;hereof (a &ldquo;<B>Material Adverse Change</B>&rdquo;), except as set forth in or contemplated
in the Disclosure Package and the Prospectus;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">the
representations, warranties and covenants set forth in Section&nbsp;2 of this Agreement are true and correct with the same force and effect
as though expressly made on and as of such date; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">the
Company and its subsidiaries have complied with all the agreements hereunder and satisfied all the conditions on its part to be performed
or satisfied hereunder at or prior to such date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">The
Company shall have requested and caused the Accountants to have furnished to the Manager, on every date specified in Section&nbsp;4(n)&nbsp;hereof
and to the extent requested by the Manager in connection with any offering of the Shares, letters (which may refer to letters previously
delivered to the Manager), dated as of such date, in form and substance satisfactory to the Manager, which letters shall cover, without
limitation, the various financial statements and disclosures contained in the Registration Statement, the Disclosure Package and the Prospectus
and other matters ordinarily covered by accountants&rsquo; &ldquo;comfort letters&rdquo; to underwriters in connection with registered
public offerings as contemplated in the Statement on Auditing Standards No.&nbsp;72, as well as confirming that they have performed a
review of any unaudited interim financial information of the Company included in the Registration Statement, the Disclosure Package and
the Prospectus in accordance with Statement on Auditing Standards No.&nbsp;100.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">References to the Prospectus
in this paragraph (e)&nbsp;include any supplement thereto at the date of the letter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">The
Company shall have furnished or caused to be furnished to the Manager, on every date specified in Section&nbsp;4(k)&nbsp;of this Agreement,
if requested by the Manager, a certificate of the Company&rsquo; Chief Financial Officer of the Company, dated as of such date, in form
and substance satisfactory to the Manager, of its Chief Financial Officer with respect to certain financial data contained in the Prospectus,
providing &ldquo;management comfort&rdquo; with respect to such information.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Since
the respective dates as of which information is disclosed in the Registration Statement, the Disclosure Package and the Prospectus, except
as otherwise stated therein, there shall not have been (i)&nbsp;any change or decrease specified in the letter or letters referred to
in paragraph (e)&nbsp;of this Section&nbsp;6 or (ii)&nbsp;Material Adverse Change, except as set forth in or contemplated in the Disclosure
Package (exclusive of any amendment or supplement thereto) the effect of which, in any case referred to in clause (i)&nbsp;or (ii)&nbsp;above,
is, in the sole judgment of the Manager, so material and adverse as to make it impractical or inadvisable to proceed with the offering
or delivery of the Shares as contemplated by the Registration Statement (exclusive of any amendment thereof), the Disclosure Package and
the Prospectus (exclusive of any amendment or supplement thereto).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 28; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">FINRA
shall not have raised any objection with respect to the fairness and reasonableness of the terms and arrangements under this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">The
Shares shall have been listed and admitted and authorized for trading on the NASDAQ, and satisfactory evidence of such actions shall have
been provided to the Manager.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(j)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Prior
to each Settlement Date and Time of Delivery, as applicable, the Company shall have furnished to the Manager such further information,
certificates and documents as the Manager may reasonably request.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If any of the conditions specified
in this Section&nbsp;6 shall not have been fulfilled when and as provided in this Agreement, or if any of the opinions and certificates
mentioned above or elsewhere in this Agreement shall not be reasonably satisfactory in form and substance to the Manager and counsel for
the Manager, this Agreement and all obligations of the applicable Manager hereunder may be canceled at, or at any time prior to, any Settlement
Date or Time of Delivery, as applicable, by the Manager with respect to itself only. Notice of such cancellation shall be given to the
Company in writing or by telephone or facsimile confirmed in writing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The documents required to
be delivered by this Section&nbsp;6 shall be delivered at the office of Latham&nbsp;&amp; Watkins LLP, counsel for the Manager, at 1271
Avenue of the Americas, New York, New York 10020, on each such date as provided in this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Indemnification
and Contribution</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">The
Company agrees to indemnify and hold harmless the Manager, its affiliates, as such term is defined in Rule&nbsp;501(b)&nbsp;under the
Act (an &ldquo;<B>Affiliate</B>&rdquo;), the directors, officers, employees and agents of the Manager, any broker-dealer affiliate of
the Manager through which Shares are sold, and each person who controls the Manager within the meaning of either the Act or the Exchange
Act and against any loss, claim, damage, liability or expense, as incurred, to which they or any of them may become subject under the
Act, the Exchange Act or other federal or state statutory law or regulation, at common law or otherwise (including in settlement of any
litigation, if such settlement is effected with the written consent of the Company or otherwise permitted by paragraph (d)&nbsp;below),
insofar as such loss, claim, damage, liability or expense (or actions in respect thereof as contemplated below) arises out of or is based
(i)&nbsp;upon any untrue statement or alleged untrue statement of a material fact contained in the Registration Statement (or any amendment
thereto) or the omission or alleged omission therefrom of a material fact required to be stated therein or necessary to make the statements
therein not misleading; or (ii)&nbsp;upon any untrue statement or alleged untrue statement of a material fact contained in any Issuer
Free Writing Prospectus or any &ldquo;issuer information&rdquo; filed or required to be filed pursuant to Rule&nbsp;433(d)&nbsp;under
the Act, the Base Prospectus, the Prospectus Supplement or any Interim Prospectus Supplement (or any amendment or supplement thereto)
or the omission or alleged omission therefrom of a material fact, in each case, necessary in order to make the statements therein, in
the light of the circumstances under which they were made, not misleading; or (iii)&nbsp;in whole or in part upon any inaccuracy in the
representations and warranties of the Company contained herein; or (iv)&nbsp;in whole or in part upon any failure of the Company to perform
its obligations hereunder or under law; and agrees to reimburse each such indemnified party, for any and all expenses (including the reasonable
fees and disbursements of counsel chosen by the indemnified party) as such expenses are reasonably incurred by them in connection with
investigating, defending, settling, compromising or paying any such loss, claim, damage, liability, expense or action; <I>provided</I>,
<I>however</I>, that the foregoing indemnity agreement shall not apply to any loss, claim, damage, liability or expense to the extent,
but only to the extent, arising out of or based upon any untrue statement or alleged untrue statement or omission or alleged omission
made in reliance upon and in conformity with written information furnished to the Company by the Manager expressly for use in the Registration
Statement (or any amendment thereto), any Issuer Free Writing Prospectus or the Prospectus (or any amendment or supplement thereto). This
indemnity agreement will be in addition to any liabilities that the Company may otherwise have.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 29; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">The
Manager agrees to indemnify and hold harmless the Company, each of its directors, each of its officers who signed the Registration Statement
and each person, if any, who controls the Company within the meaning of the Act or the Exchange Act, against any loss, claim, damage,
liability or expense, as incurred, to which the Company or any such director, officer or controlling person may become subject, under
the Act, the Exchange Act, or other federal or state statutory law or regulation, or at common law or otherwise (including in settlement
of any litigation, if such settlement is effected with the written consent of the Manager or otherwise permitted by paragraph (d)&nbsp;below),
insofar as such loss, claim, damage, liability or expense (or actions in respect thereof as contemplated below) arises out of or is based
(i)&nbsp;upon any untrue statement or alleged untrue statement of a material fact contained in the Registration Statement (or any amendment
thereto) or the omission or alleged omission therefrom of a material fact required to be stated therein or necessary to make the statements
therein not misleading; or (ii)&nbsp;upon any untrue statement or alleged untrue statement of a material fact contained in any Issuer
Free Writing Prospectus or any &ldquo;issuer information&rdquo; filed or required to be filed pursuant to Rule&nbsp;433(d)&nbsp;under
the Act, the Base Prospectus, the Prospectus Supplement or any Interim Prospectus Supplement (or any amendment or supplement thereto)
or the omission or alleged omission therefrom of a material fact, in each case, necessary in order to make the statements therein, in
the light of the circumstances under which they were made, not misleading, in each case to the extent, but only to the extent, that such
untrue statement or alleged untrue statement or omission or alleged omission was made in the Registration Statement, the Base Prospectus,
any Issuer Free Writing Prospectus, any Prospectus Supplement or any Interim Prospectus Supplement (or any amendment or supplement thereto),
in reliance upon and in conformity with written information furnished to the Company by the Manager expressly for use therein; and to
reimburse the Company, or any such director, officer or controlling person for any legal and other expense reasonably incurred by the
Company, or any such director, officer or controlling person in connection with investigating, defending, settling, compromising or paying
any such loss, claim, damage, liability, expense or action. The indemnity agreement set forth in this Section&nbsp;7(b)&nbsp;shall be
in addition to any liabilities that the Manager may otherwise have. The Company acknowledges that with respect to the Manager, the name
of the Manager constitutes the only information furnished in writing by or on behalf of the Manager for inclusion in the Registration
Statement, the Base Prospectus, any Issuer Free Writing Prospectus, any Prospectus Supplement or any Interim Prospectus Supplement (or
any amendment or supplement thereto).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 30; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Promptly
after receipt by an indemnified party under this Section&nbsp;7 of notice of the commencement of any action, such indemnified party will,
if a claim in respect thereof is to be made against the indemnifying party under this Section&nbsp;7, notify the indemnifying party in
writing of the commencement thereof; but the omission to so notify the indemnifying party will not relieve it from any liability which
it may have to any indemnified party for contribution or otherwise than under the indemnity agreement contained in paragraph (a)&nbsp;or
(b)&nbsp;above or to the extent it is not prejudiced (through the forfeiture of substantive rights or defenses) as a proximate result
of such failure. In case any such action is brought against any indemnified party and such indemnified party seeks or intends to seek
indemnity from an indemnifying party, the indemnifying party will be entitled to participate in, and, to the extent that it shall elect,
jointly with all other indemnifying parties similarly notified, by written notice delivered to the indemnified party promptly after receiving
the aforesaid notice from such indemnified party, to assume the defense thereof with counsel reasonably satisfactory to such indemnified
party; <I>provided</I>, <I>however</I>, if the defendants in any such action include both the indemnified party and the indemnifying party
and the indemnified party shall have reasonably concluded that a conflict may arise between the positions of the indemnifying party and
the indemnified party in conducting the defense of any such action or that there may be legal defenses available to it and/or other indemnified
parties which are different from or additional to those available to the indemnifying party, the indemnified party or parties shall have
the right to select separate counsel to assume such legal defenses and to otherwise participate in the defense of such action on behalf
of such indemnified party or parties. Upon receipt of notice from the indemnifying party to such indemnified party of such indemnifying
party&rsquo;s election to assume the defense of such action and approval by the indemnified party of counsel, the indemnifying party will
not be liable to such indemnified party under this Section&nbsp;7 for any legal or other expenses subsequently incurred by such indemnified
party in connection with the defense thereof unless (i)&nbsp;the indemnified party shall have employed separate counsel in accordance
with the proviso to the next preceding sentence (it being understood, however, that the indemnifying party shall not be liable for the
expenses of more than one separate counsel (together with local counsel), approved by the indemnifying party (the Manager in the case
of Section&nbsp;7(b)&nbsp;and Section&nbsp;7(e)), representing the indemnified parties who are parties to such action), (ii)&nbsp;the
indemnifying party shall not have employed counsel reasonably satisfactory to the indemnified party to represent the indemnified party
within a reasonable time after notice of commencement of the action, in each of which cases the fees and expenses of counsel shall be
at the expense of the indemnifying party or (iii)&nbsp;the indemnifying party shall authorize the indemnified party to employ separate
counsel at the expense of the indemnifying party.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">The
indemnifying party under this Section&nbsp;7 shall not be liable for any settlement of any proceeding effected without its written consent,
but if settled with such consent or if there be a final judgment for the plaintiff, the indemnifying party agrees to indemnify the indemnified
party against any loss, claim, damage, liability or expense by reason of such settlement or judgment. Notwithstanding the foregoing sentence,
if at any time an indemnified party shall have requested an indemnifying party to reimburse the indemnified party for reasonable and documented
fees and expenses of counsel as contemplated by Section&nbsp;7(c)&nbsp;hereof, the indemnifying party agrees that it shall be liable for
any settlement of any proceeding effected without its written consent if (i)&nbsp;such settlement is entered into more than 60 days after
receipt by such indemnifying party of the aforesaid request and (ii)&nbsp;such indemnifying party shall not have reimbursed the indemnified
party in accordance with such request prior to the date of such settlement. No indemnifying party shall, without the prior written consent
of the indemnified party, effect any settlement, compromise or consent to the entry of judgment in any pending or threatened action, suit
or proceeding in respect of which any indemnified party is or could have been a party and indemnity was or could have been sought hereunder
by such indemnified party, unless such settlement, compromise or consent (i)&nbsp;includes an unconditional release of such indemnified
party from all liability on claims that are the subject matter of such action, suit or proceeding and (ii)&nbsp;does not include a statement
as to or an admission of fault, culpability or a failure to act, by or on behalf of any indemnified party.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 31; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">If
the indemnification provided for in this Section&nbsp;7 is for any reason held to be unavailable to or otherwise insufficient to hold
harmless an indemnified party in respect of any losses, claims, damages, liabilities or expenses referred to therein, then each indemnifying
party shall contribute to the aggregate amount paid or payable by such indemnified party, as incurred, as a result of any losses, claims,
damages, liabilities or expenses referred to therein (i)&nbsp;in such proportion as is appropriate to reflect the relative benefits received
by the Company, on the one hand, and the Manager, on the other hand, from the offering of the Shares pursuant to this Agreement, or (ii)&nbsp;if
the allocation provided by clause (i)&nbsp;above is not permitted by applicable law, in such proportion as is appropriate to reflect not
only the relative benefits referred to in clause (i)&nbsp;above but also the relative fault of the Company, on the one hand, and the Manager,
on the other hand, in connection with the statements or omissions or inaccuracies in the representations and warranties herein which resulted
in such losses, claims, damages, liabilities or expenses, as well as any other relevant equitable considerations. The relative benefits
received by the Company shall be deemed to be equal to the total net proceeds from the offering (before deducting expenses) received by
them, and benefits received by the Manager shall be deemed to be equal to the total compensation received by the Manager under Section&nbsp;3(c)&nbsp;of
this Agreement, in each case as determined by this Agreement or any applicable Terms Agreement. The relative fault of the Company, on
the one hand, and the Manager, on the other hand, shall be determined by reference to, among other things, whether any such untrue or
alleged untrue statement of a material fact or omission or alleged omission to state a material fact or any such inaccurate or alleged
inaccurate representation or warranty relates to information supplied by the Company, on the one hand, or the Manager, on the other hand,
and the parties&rsquo; relative intent, knowledge, access to information and opportunity to correct or prevent such statement or omission.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The amount paid or payable
by a party as a result of the losses, claims, damages, liabilities and expenses referred to above shall be deemed to include, subject
to the limitations set forth in Section&nbsp;7(c), any legal or other fees or expenses reasonably incurred by such party in connection
with investigating or defending any action or claim. The provisions set forth in Section&nbsp;7(c)&nbsp;with respect to notice of commencement
of any action shall apply if a claim for contribution is to be made under this Section&nbsp;7(e); <I>provided</I>, <I>however</I>, that
no additional notice shall be required with respect to any action for which notice has been given under Section&nbsp;7(c)&nbsp;for purposes
of indemnification.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company and the Manager
agree that it would not be just and equitable if contribution pursuant to this Section&nbsp;7(e)&nbsp;were determined by pro rata allocation
or by any other method of allocation which does not take account of the equitable considerations referred to in this Section&nbsp;7(e).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 32; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Notwithstanding the provisions
of this Section&nbsp;7(e), no Manager shall be required to contribute any amount in excess of the discounts and commissions received by
the Manager in connection with the Shares sold by it pursuant to this Agreement and any applicable Terms Agreement in the specific transaction
or transactions giving rise to the contribution obligation. No person guilty of fraudulent misrepresentation (within the meaning of Section&nbsp;11(f)&nbsp;of
the Act) shall be entitled to contribution from any person who was not guilty of such fraudulent misrepresentation. For purposes of this
Section&nbsp;7(e), each Affiliate, director, officer, employee and agent of the Manager, each person, if any, who controls the Manager
within the meaning of the Act and the Exchange Act and any broker-dealer affiliate of the Manager through which Shares are sold shall
have the same rights to contribution as the Manager, and each director of the Company or each officer of the Company who signed the Registration
Statement, and each person, if any, who controls the Company within the meaning of the Act and the Exchange Act shall have the same rights
to contribution as the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Termination</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">The
Company shall have the right, by giving written notice as hereinafter specified, to terminate the provisions of this Agreement relating
to the solicitation of offers to purchase the Shares in its sole discretion at any time. Any such termination shall be without liability
of any party to any other party except that (i)&nbsp;if Shares have been sold through the Manager for the Company, then Section&nbsp;4(s)&nbsp;shall
remain in full force and effect with respect to the Manager and the Company, (ii)&nbsp;with respect to any pending sale, through the Manager
for the Company, the obligations of the Company, including in respect of compensation of the Manager, shall remain in full force and effect
notwithstanding the termination and (iii)&nbsp;the provisions of Sections 2, 5, 7, 9, 10, 12 and 14 of this Agreement shall remain in
full force and effect notwithstanding such termination.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">The
Manager shall have the right, by giving written notice as hereinafter specified, to terminate the provisions of this Agreement relating
to the solicitation of offers to purchase the Shares in its sole discretion at any time. Any such termination shall be without liability
of any party to any other party except that the provisions of Sections 2, 5, 7, 9, 10, 12 and 14 of this Agreement shall remain in full
force and effect with respect to the Manager notwithstanding such termination.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">This
Agreement shall remain in full force and effect unless terminated pursuant to Sections 8(a)&nbsp;or (b)&nbsp;above or otherwise by mutual
agreement of the parties; <I>provided</I> that any such termination by mutual agreement shall in all cases be deemed to provide that Sections
2, 5, 7 and 9 shall remain in full force and effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Any
termination of this Agreement shall be effective on the date specified in such notice of termination; <I>provided</I> that such termination
shall not be effective until the close of business on the date of receipt of such notice by the Manager or the Company, as the case may
be. If such termination shall occur prior to the Settlement Date or Time of Delivery for any sale of the Shares, such sale shall, subject
to Section&nbsp;6 hereof, settle in accordance with the provisions of Section&nbsp;3(e)&nbsp;of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 33; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">In
the case of any purchase of Shares by the Manager pursuant to a Terms Agreement, the obligations of the Manager pursuant to such Terms
Agreement shall be subject to termination, in the absolute discretion of the Manager, by notice given to the Company prior to the Time
of Delivery relating to such Shares, if at any time prior to such delivery and payment (i)&nbsp;trading or quotation in any of the Company&rsquo;s
securities shall have been suspended or limited by the Commission or by NASDAQ, or trading in securities generally on either the NASDAQ
or the New York Stock Exchange shall have been suspended or limited, or minimum or maximum prices shall have been generally established
on any of such stock exchanges by the Commission or FINRA; (ii)&nbsp;a general banking moratorium shall have been declared by any of federal
or New York authorities; (iii)&nbsp;there shall have occurred any outbreak or escalation of national or international hostilities or any
crisis or calamity involving the United States, or any change in the United States or international financial markets, or any substantial
change or development involving a prospective substantial change in United States&rsquo; or international political, financial or economic
conditions, as in the judgment of the Manager is material and adverse and makes it impracticable or inadvisable to proceed with the offering
or delivery of the Shares in the manner and on the terms described in the Disclosure Package and the Prospectus or to enforce contracts
for the sale of securities; (iv)&nbsp;in the judgment of the Manager there shall have occurred any Material Adverse Change or (v)&nbsp;there
shall have occurred a material disruption in commercial banking or securities settlement or clearance services in the United States.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Representations
and Indemnities to Survive</U>. The respective agreements, representations, warranties, indemnities and other statements of the Company,
the officers of the Company and of the Manager set forth in or made pursuant to this Agreement will remain in full force and effect, regardless
of any investigation made by the Manager or the Company or any of the officers, directors, employees, agents or controlling persons referred
to in Section&nbsp;7 hereof, and will survive delivery of and payment for the Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Notices</U>.
All communications hereunder will be in writing and effective only on receipt, and:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If sent to Goldman, will be
mailed, delivered or telefaxed to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Goldman Sachs&nbsp;&amp; Co. LLC<BR>
200 West Street<BR>
New York, New York 10282<BR>
Facsimile: (212) 902-9316<BR>
Attention: Registration Department</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">with a copy to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Latham&nbsp;&amp; Watkins LLP</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">1271 Avenue of the Americas</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">New York, New York 10020</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Attention: Nathan Ajiashvili and Alison Haggerty</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If sent to the Company, will
be mailed or delivered to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Amicus Therapeutics,&nbsp;Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">3675 Market Street</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Philadelphia, PA 19104</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Attention: Legal Department, Office of the General Counsel</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 34; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">with a copy to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Troutman Pepper Hamilton Sanders LLP</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">400 Berwyn Park</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">899 Cassatt Road</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Berwyn, PA 19312</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Attention: Scott R. Jones</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any party hereto may change
the address for receipt of communications by giving written notice to the others.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Successors</U>.
This Agreement will inure to the benefit of and be binding upon the parties hereto and their respective successors and the officers, directors,
employees, agents and controlling persons referred to in Section&nbsp;7 hereof, and no other person will have any right or obligation
hereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>No
Fiduciary Duty</U>. The Company hereby acknowledges that (a)&nbsp;the purchase and sale of the Shares pursuant to this Agreement is an
arm&rsquo;s-length commercial transaction between the Company, on the one hand, and the Manager and any affiliate through which it may
be acting, on the other, (b)&nbsp;the Manager is acting solely as sales agent and/or principal in connection with the purchase and sale
of the Company&rsquo;s securities and not as a fiduciary of the Company and (c)&nbsp;the Company&rsquo;s engagement of the Manager in
connection with the offering and the process leading up to the offering is as an independent contractor and not in any other capacity.
Furthermore, the Company agrees that it is solely responsible for making its own judgments in connection with the offering (irrespective
of whether the Manager has advised or is currently advising it on related or other matters). The Company agrees that it will not claim
that the Manager has rendered advisory services of any nature or respect, or owe an agency, fiduciary or similar duty to the Company,
in connection with the transactions contemplated by this Agreement or the process leading thereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">13.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Integration</U>.
This Agreement and any Terms Agreement supersede all prior agreements and understandings (whether written or oral) between the Company
and the Manager with respect to the subject matter hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Applicable
Law</U>. This Agreement and any Terms Agreement will be governed by and construed in accordance with the laws of the State of New York
applicable to contracts made and to be performed within the State of New York.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Waiver
of Jury Trial</U>. The Company hereby irrevocably waives, to the fullest extent permitted by applicable law, any and all right to trial
by jury in any legal proceeding arising out of or relating to this Agreement, any Terms Agreement or the transactions contemplated hereby
or thereby.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">16.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Counterparts</U>.
This Agreement and any Terms Agreement may be signed in one or more counterparts, each of which shall constitute an original and all of
which together shall constitute one and the same agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 35; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">17.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Headings</U>.
The section headings used in this Agreement and any Terms Agreement are for convenience only and shall not affect the construction hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">18.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Recognition
of the U.S. Special Resolution Regimes</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">In
the event that the Manager that is a Covered Entity and becomes subject to a proceeding under a U.S. Special Resolution Regime, the transfer
from the Manager of this Agreement, and any interest and obligation in or under this Agreement, will be effective to the same extent as
the transfer would be effective under the U.S. Special Resolution Regime if this Agreement, and any such interest and obligation, were
governed by the laws of the United States or a state of the United States.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">In
the event that the Manager is a Covered Entity or a BHC Act Affiliate of the Manager becomes subject to a proceeding under a U.S. Special
Resolution Regime, Default Rights under this Agreement that may be exercised against the Manager are permitted to be exercised to no greater
extent than such Default Rights could be exercised under the U.S. Special Resolution Regime if this Agreement were governed by the laws
of the United States or a state of the United States.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As used in this Section&nbsp;18:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<B>BHC
Act Affiliate</B>&rdquo; has the meaning assigned to the term &ldquo;affiliate&rdquo; in, and shall be interpreted in </FONT>accordance
with, 12 U.S.C. &sect; 1841(k).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<B>Covered
</B></FONT><B>Entity</B>&rdquo; means any of the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(i)&nbsp;a
 &ldquo;covered entity&rdquo; as that term is defined in, and interpreted in accordance </FONT>with, 12 C.F.R. &sect; 252.82(b);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(ii)&nbsp;a
 &ldquo;covered bank&rdquo; as that term is defined in, and interpreted in accordance </FONT>with, 12 C.F.R. &sect; 47.3(b); or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(iii)&nbsp;a
 &ldquo;covered FSI&rdquo; as that term is defined in, and interpreted in accordance </FONT>with, 12 C.F.R. &sect; 382.2(b).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Default Right</B>&rdquo;
has the meaning assigned to that term in, and shall be interpreted in accordance with, 12 C.F.R. &sect;&sect; 252.81, 47.2 or 382.1, as
applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<B>U.S.
Special Resolution Regime</B>&rdquo; means each of (i)&nbsp;the Federal Deposit Insurance </FONT>Act and the regulations promulgated thereunder
and (ii)&nbsp;Title II of the Dodd-Frank Wall Street Reform and Consumer Protection Act and the regulations promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">19.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Definitions</U>.
The terms that follow, when used in this Agreement and any Terms Agreement, shall have the meanings indicated.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Act</B>&rdquo; shall
mean the Securities Act of 1933, as amended, and the rules&nbsp;and regulations of the Commission promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 36; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Applicable Time</B>&rdquo;
shall mean, with respect to any Shares, the time of sale of such Shares pursuant to this Agreement or any relevant Terms Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Base Prospectus</B>&rdquo;
shall mean the base prospectus referred to in Section&nbsp;2(a)&nbsp;above contained in the Registration Statement at the Execution Time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Business Day</B>&rdquo;
shall mean any day other than a Saturday, a Sunday or a legal holiday or a day on which banking institutions or trust companies are authorized
or obligated by law to close in New York City.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Commission</B>&rdquo;
shall mean the Securities and Exchange Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Disclosure Package</B>&rdquo;
shall mean (i)&nbsp;the Base Prospectus, (ii)&nbsp;the Prospectus Supplement, (iii)&nbsp;the most recently filed Interim Prospectus Supplement,
if any, (iv)&nbsp;the Issuer Free Writing Prospectuses, if any, identified in Schedule I hereto, (v)&nbsp;the public offering price of
Shares sold at the relevant Applicable Time as specified in a Terms Agreement and (vi)&nbsp;any other Free Writing Prospectus that the
parties hereto shall hereafter expressly agree in writing to treat as part of the Disclosure Package.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Effective Date</B>&rdquo;
shall mean each date and time that the Registration Statement and any post-effective amendment or amendments thereto became or becomes
effective.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Exchange Act</B>&rdquo;
shall mean the Securities Exchange Act of 1934, as amended, and the rules&nbsp;and regulations of the Commission promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Execution Time</B>&rdquo;
shall mean the date and time that this Agreement is executed and delivered by the parties hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Free Writing Prospectus</B>&rdquo;
shall mean a free writing prospectus, as defined in Rule&nbsp;405.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Interim Prospectus
Supplement</B>&rdquo; shall mean the prospectus supplement relating to the Shares prepared and filed pursuant to Rule&nbsp;424(b)&nbsp;from
time to time as provided by Section&nbsp;4(q)&nbsp;of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Issuer Free Writing
Prospectus</B>&rdquo; shall mean an issuer free writing prospectus, as defined in Rule&nbsp;433.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Prospectus</B>&rdquo;
shall mean the Base Prospectus, as supplemented by the Prospectus Supplement and the most recently filed Interim Prospectus Supplement
(if any).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Prospectus Supplement</B>&rdquo;
shall mean the most recent prospectus supplement relating to the Shares that was first filed pursuant to Rule&nbsp;424(b)&nbsp;at or prior
to the Execution Time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Registration Statement</B>&rdquo;
shall mean the registration statement referred to in Section&nbsp;2(a)&nbsp;above, including exhibits and financial statements and any
prospectus supplement relating to the Shares that is filed with the Commission pursuant to Rule&nbsp;424(b)&nbsp;and deemed part of such
registration statement pursuant to Rule&nbsp;430B, as amended on each Effective Date and, in the event any post-effective amendment thereto
becomes effective, shall also mean such registration statement as so amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 37; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Rule&nbsp;158</B>,&rdquo;
 &ldquo;<B>Rule&nbsp;163</B>,&rdquo; &ldquo;<B>Rule&nbsp;164</B>,&rdquo; &ldquo;<B>Rule&nbsp;172</B>,&rdquo; &ldquo;<B>Rule&nbsp;405</B>,&rdquo;
 &ldquo;<B>Rule&nbsp;415</B>,&rdquo; &ldquo;<B>Rule&nbsp;424</B>,&rdquo; &ldquo;<B>Rule&nbsp;430B</B>&rdquo; and &ldquo;<B>Rule&nbsp;433</B>&rdquo;
refer to such rules&nbsp;under the Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><I>[Signature Page&nbsp;Follows]</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 38; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If the foregoing is in accordance
with your understanding of our agreement, please sign and return to us the enclosed duplicate hereof, whereupon this letter and your acceptance
shall represent a binding agreement among the Company and the Manager.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Very truly yours,</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>AMICUS THERAPEUTICS,&nbsp;INC.</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="text-align: justify; font-size: 10pt; width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: justify; font-size: 10pt; width: 47%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Daphne Quimi</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:
    Daphne Quimi</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:
    &nbsp;&nbsp;Chief Financial Officer</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-variant: small-caps">Signature
Page&nbsp;to Equity Distribution Agreement</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 39 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CONFIRMED AND ACCEPTED,</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-indent: 0.25in; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">as of the date first written above:</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="font-size: 10pt">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Goldman Sachs&nbsp;&amp; Co. LLC</B></FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="font-size: 10pt">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; font-size: 10pt; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: justify; font-size: 10pt; width: 45%">/s/ Danielle Freeman</TD>
    <TD STYLE="width: 50%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt">Danielle Freeman</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt">Managing Director</TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-variant: small-caps">Signature
Page&nbsp;to Equity Distribution Agreement</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 40 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>SCHEDULE I</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Schedule of Free Writing Prospectuses included
in the Disclosure Package</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">None</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 41 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Schedule I</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><B><U>ANNEX&nbsp;I</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; text-transform: uppercase"><B>AMICUS
THERAPEUTICS,&nbsp;INC.</B></FONT><BR>
Common Stock ($0.01 par value)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>TERMS AGREEMENT</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">[&nbsp;<FONT STYLE="font-family: Wingdings">&#108;</FONT>&nbsp;], 2022</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Goldman Sachs&nbsp;&amp; Co. LLC</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">200 West Street</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">New York, New York 10282</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Dear Sirs:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Amicus Therapeutics,&nbsp;Inc.,
a Delaware corporation (the &ldquo;<U>Company</U>&rdquo;) proposes, subject to the terms and conditions stated herein and in the Equity
Distribution Agreement, dated [&nbsp;<FONT STYLE="font-family: Wingdings">&#108;</FONT>&nbsp;], 2022 (the &ldquo;<U>Equity Distribution Agreement</U>&rdquo;), among the Company,
Goldman Sachs&nbsp;&amp; Co. LLC, to issue and sell to Goldman Sachs&nbsp;&amp; Co. LLC, the securities specified in the Schedule I hereto
(the &ldquo;<U>Purchased Shares</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Each of the provisions of
the Equity Distribution Agreement not specifically related to the solicitation by the Manager, as agent of the Company, of offers to purchase
securities is incorporated herein by reference in its entirety, and shall be deemed to be part of this Terms Agreement to the same extent
as if such provisions had been set forth in full herein. Each of the representations and warranties set forth therein shall be deemed
to have been made at and as of the date of this Terms Agreement and the Time of Delivery, except that each representation and warranty
in Section&nbsp;2 of the Equity Distribution Agreement which makes reference to the Prospectus (as therein defined) shall be deemed to
be a representation and warranty as of the date of the Equity Distribution Agreement in relation to the Prospectus, and also a representation
and warranty as of the date of this Terms Agreement and the Time of Delivery in relation to the Prospectus as amended and supplemented
to relate to the Purchased Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">An amendment to the Registration
Statement (as defined in the Equity Distribution Agreement), or a supplement to the Prospectus, as the case may be, relating to the Purchased
Shares, in the form heretofore delivered to the Manager is now proposed to be filed with the Securities and Exchange Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Subject to the terms and conditions
set forth herein and in the Equity Distribution Agreement which are incorporated herein by reference, the Company agrees to issue and
sell to the Manager and the latter agrees to purchase from the Company the number of shares of the Purchased Shares at the time and place
and at the purchase price set forth in the Schedule I hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If the foregoing is in accordance
with your understanding, please sign and return to us a counterpart hereof, whereupon this Terms Agreement, including those provisions
of the Equity Distribution Agreement incorporated herein by reference, shall constitute a binding agreement between the Manager and the
Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 42; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Exhibit A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>AMICUS THERAPEUTICS,&nbsp;INC.</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;[&nbsp;</FONT><FONT STYLE="font-family: Wingdings; font-size: 10pt">l</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;]</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="text-align: justify; font-size: 10pt; width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: justify; font-size: 10pt; width: 47%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ACCEPTED as of the date first written above.</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="font-size: 10pt">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>GOLDMAN SACHS&nbsp;&amp; CO. LLC</B></FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="font-size: 10pt">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="font-size: 10pt">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; width: 47%">&nbsp;</TD>
    <TD STYLE="width: 50%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 43; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Exhibit A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><B>Schedule I to the Terms Agreement</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Title of Purchased Shares:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Common Stock</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Number of Shares of Purchased Shares:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Price to Public:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Purchase Price by Goldman Sachs&nbsp;&amp; Co.
LLC:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Method of and Specified Funds for Payment of Purchase
Price:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">By wire transfer to a bank account specified by
the Company in same day funds.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Method of Delivery:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Free delivery of the Shares to the Manager&rsquo;s
account at The Depository Trust Company in return for payment of the purchase price.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Time of Delivery:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Closing Location:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Documents to be Delivered:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following documents referred to in the Equity
Distribution Agreement shall be delivered as a condition to the closing at the Time of Delivery:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">The
opinion referred to in Section&nbsp;4(l).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">The
opinion referred to in Section&nbsp;4(m).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">The
accountants&rsquo; letter referred to in Section&nbsp;4(n).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">The
officers&rsquo; certificate referred to in Section&nbsp;4(k).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Such
other documents as the Manager shall reasonably request.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 44; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Exhibit A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>3
<FILENAME>tm2229838d1_ex5-1.htm
<DESCRIPTION>EXHIBIT 5.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: right; margin: 0"><B>Exhibit 5.1</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 1pt; width: 54%; padding-right: 1pt; padding-bottom: 1pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Troutman Pepper Hamilton Sanders LLP<BR>
    400 Berwyn Park, 899 Cassatt Road<BR>
    Berwyn, PA 19312-1183</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">troutman.com</P></TD>
    <TD STYLE="padding-top: 1pt; text-align: right; width: 46%; font-size: 10pt; padding-right: 1pt; padding-bottom: 1pt"><IMG SRC="tm2229838d1_ex5-1img001.jpg" ALT=""></TD></TR>
  </TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">November&nbsp;7, 2022</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Amicus Therapeutics,&nbsp;Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">3675 Market Street</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Philadelphia, PA 19104</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 1in">&nbsp;</TD>
    <TD STYLE="width: 0.5in; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Re:</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities Registered under Registration Statement on Form&nbsp;S-3</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Ladies and Gentlemen:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">Reference is made to (i)&nbsp;the
Registration Statement on Form&nbsp;S-3 (Registration No.&nbsp;333-262987) (as amended from time to time, the &ldquo;<B><I>Registration
Statement</I></B>&rdquo;) filed by Amicus Therapeutics,&nbsp;Inc., a Delaware corporation (the &ldquo;<B><I>Company</I></B>&rdquo;), with
the U.S. Securities and Exchange Commission (the &ldquo;<B><I>Commission</I></B>&rdquo;) on February&nbsp;24, 2022, under the Securities
Act of 1933, as amended (the &ldquo;<B><I>Securities Act</I></B>&rdquo;), and which became automatically effective upon the filing thereof,
for the registration of, among other things, an indeterminate number of shares of Common Stock, par value $0.01 per share, of the Company
(&ldquo;<B><I>Common Stock</I></B>&rdquo;), which may be issued as set forth in the Registration Statement and the prospectus contained
therein (the &ldquo;<B><I>Base Prospectus</I></B>&rdquo;) and (ii)&nbsp;the prospectus supplement, dated November&nbsp;7, 2022 (the &ldquo;<B><I>Prospectus
Supplement</I></B>&rdquo; and together with the Base Prospectus, the &ldquo;<B><I>Prospectus</I></B>&rdquo;), relating to the offering
by the Company of up to $250,000,000 of shares of Common Stock (the &ldquo;<B><I>Shares</I></B>&rdquo;), all of which may be issued from
time to time on a delayed or continuous basis pursuant to Rule&nbsp;415 under the Securities Act at an indeterminate offering price, as
set forth in the Registration Statement and the Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">We understand that the Shares
are to be offered and sold in the manner set forth in the Prospectus pursuant to an Equity Distribution Agreement, dated November&nbsp;7,
2022, between the Company and Goldman Sachs&nbsp;&amp; Co. LLC, as Agent (the &ldquo;<B><I>Distribution Agreement</I></B>&rdquo;), which
has been incorporated by reference into the Registration Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">We have acted as Company counsel
in connection with the preparation of the Registration Statement and Prospectus, as well as with the issue and sale by the Company of
the Shares pursuant to the Distribution Agreement. We are familiar with the proceedings taken by the Board of Directors of the Company
(the &ldquo;<B><I>Board of Directors</I></B>&rdquo;) in connection with the registration of the Shares, the authorization of the execution
and delivery of the Distribution Agreement and the authorization, sale and issuance of the Shares. We have examined all such documents
that we considered necessary to enable us to render this opinion, including but not limited to the Registration Statement, the Prospectus,
the Distribution Agreement, the Company&rsquo;s Restated Certificate of Incorporation, as amended, and the Company&rsquo;s Restated Bylaws,
as amended, in effect on the date hereof, certain resolutions of the Board of Directors, corporate records, and instruments, and such
laws and regulations as we have deemed necessary for purposes of rendering the opinions set forth herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">In our examination, we have
assumed: (a)&nbsp;the legal capacity of all natural persons; (b)&nbsp;the genuineness of all signatures; (c)&nbsp;the authenticity of
all documents submitted to us as originals; (d)&nbsp;the conformity to original documents of all documents submitted to us as certified,
conformed, photostatic or facsimile copies; (e)&nbsp;the authenticity of the originals of such latter documents; (f)&nbsp;the truth, accuracy
and completeness of the information, representations and warranties contained in the records, documents, instruments, certificates and
records we have reviewed; and (g)&nbsp;the absence of any undisclosed modifications to the agreements and instruments reviewed by us.
As to
any facts material to the opinions expressed herein, which were not independently established or verified, we have relied upon statements
and representations of officers and other representatives of the Company and others.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Amicus Therapeutics,&nbsp;Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Page&nbsp;2</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">We express no opinion herein
as to the law of any state or jurisdiction other than the laws of the State of Delaware, including statutory provisions and all applicable
provisions of the Delaware Constitution and reported judicial decisions interpreting such laws of the State of Delaware, and the federal
laws of the United States of America.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">Based upon the foregoing, we
are of the opinion that, as of the date hereof, when the Shares have been (i)&nbsp;sold pursuant to the Distribution Agreement and duly
registered on the books of the transfer agent and registrar therefor in the name or on behalf of the purchasers, and (ii)&nbsp;issued
by the Company against payment therefor for an aggregate offering price that does not exceed $250,000,000, (a)&nbsp;the issuance and sale
of the Shares will have been duly authorized by all necessary corporate action of the Company, and (b)&nbsp;when issued and delivered
by the Company against payment therefor as set forth in the Prospectus, will be validly issued, fully paid and non-assessable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">We assume no obligation to supplement
this opinion if any applicable law changes after the date hereof or if we become aware of any fact that might change the opinion expressed
herein after the date hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">We hereby consent to the filing
of this opinion as a part of the Registration Statement and to the reference of our firm in the Prospectus Supplement under the caption
 &ldquo;Legal Matters&rdquo;. In giving such consent, we do not hereby admit that we are in the category of persons whose consent is required
under Section&nbsp;7 of the Securities Act or the rules&nbsp;and regulations of the Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 50%; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Very truly yours,</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>/s/ Troutman Pepper Hamilton Sanders LLP</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Troutman Pepper Hamilton Sanders LLP</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>fold-20221107.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.16b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: +aA5w7xRiXgen8uLa3ZcWaOBibOdzZR+iYkxtmBwbVnafyUhA67y/CNnj/e2IXMN -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:srt-types="http://fasb.org/srt-types/2021-01-31" xmlns:fold="http://amicustherapeutics.com/20221107" elementFormDefault="qualified" targetNamespace="http://amicustherapeutics.com/20221107">
    <annotation>
      <appinfo>
	<link:roleType roleURI="http://amicustherapeutics.com/role/Cover" id="Cover">
	  <link:definition>00000001 - Document - Cover</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:linkbaseRef xlink:type="simple" xlink:href="fold-20221107_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="fold-20221107_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2021q4" schemaLocation="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" />
    <import namespace="http://fasb.org/us-gaap/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd" />
    <import namespace="http://fasb.org/us-types/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2021" schemaLocation="https://xbrl.sec.gov/country/2021/country-2021.xsd" />
    <import namespace="http://fasb.org/srt/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd" />
    <import namespace="http://fasb.org/srt-types/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>fold-20221107_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.16b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>fold-20221107_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.16b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://amicustherapeutics.com/role/Cover" xlink:href="fold-20221107.xsd#Cover" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://amicustherapeutics.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>tm2229838d1_ex5-1img001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2229838d1_ex5-1img001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !- +4# 2(  A$! Q$!_\0
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MD:/I^A:>MAIELMO;*S,(U)/).3R235ZBBN-N^K/*;;=V%%%%(04444 %%%%
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FN[^;Y?EYW'/3)_G6_14.<FK,S=6;BXMZ-W^84445!D%%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140087245223040">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Nov. 07, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Nov.  07,  2022<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-33497<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">AMICUS THERAPEUTICS, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001178879<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">71-0869350<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">3675 Market Street<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Philadelphia<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">PA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">19104<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">215<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">921-7600<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock Par Value $0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">FOLD<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>tm2229838d1_8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2021q4"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="fold-20221107.xsd" xlink:type="simple"/>
    <context id="From2022-11-07to2022-11-07">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
        </entity>
        <period>
            <startDate>2022-11-07</startDate>
            <endDate>2022-11-07</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:EntityCentralIndexKey contextRef="From2022-11-07to2022-11-07">0001178879</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="From2022-11-07to2022-11-07">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="From2022-11-07to2022-11-07">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="From2022-11-07to2022-11-07">2022-11-07</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="From2022-11-07to2022-11-07">AMICUS THERAPEUTICS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2022-11-07to2022-11-07">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="From2022-11-07to2022-11-07">001-33497</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="From2022-11-07to2022-11-07">71-0869350</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2022-11-07to2022-11-07">3675 Market Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="From2022-11-07to2022-11-07">Philadelphia</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2022-11-07to2022-11-07">PA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="From2022-11-07to2022-11-07">19104</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2022-11-07to2022-11-07">215</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2022-11-07to2022-11-07">921-7600</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="From2022-11-07to2022-11-07">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="From2022-11-07to2022-11-07">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="From2022-11-07to2022-11-07">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="From2022-11-07to2022-11-07">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="From2022-11-07to2022-11-07">Common Stock Par Value $0.01</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2022-11-07to2022-11-07">FOLD</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2022-11-07to2022-11-07">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="From2022-11-07to2022-11-07">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>10
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M2.Y&%K7>3SR)3:C-"7L\3-F&+[A^3CT%([M4"43,DTS(A"B^'ED3>GWCMDU
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M,AF**I9P6B#BR2!M:59]L$].M.=Y%S?W1:[-XPFNWPQP>'3^ 5!+ P04
M" ##.F=599!YDAD!  #/ P  $P   %M#;VYT96YT7U1Y<&5S72YX;6RMDTU.
MPS 0A:\295LE+BQ8H*8;8 M=< %C3QJK_I-G6M+;,T[:2J 2%85-K'C>O,^>
MEZS>CQ&PZ)WUV)0=47P4 E4'3F(=(GBNM"$Y2?R:MB)*M9-;$/?+Y8-0P1-X
MJBA[E.O5,[1R;ZEXZ7D;3?!-F<!B63R-PLQJ2AFC-4H2U\7!ZQ^4ZD2HN7/0
M8&<B+EA0BJN$7/D=<.I[.T!*1D.QD8E>I6.5Z*U .EK >MKBRAE#VQH%.JB]
MXY8:8P*IL0,@9^O1=#%-)IXPC,^[V?S!9@K(RDT*$3FQ!'_'G2/)W55D(TAD
MIJ]X(;+U[/M!3EN#OI'-X_T,:3?D@6)8YL_X>\87_QO.\1'"[K\_L;S63AI_
MYHOA/UY_ 5!+ 0(4 Q0    ( ,,Z9U4'04UB@0   +$    0
M  "  0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ PSIG58K^V47N
M    *P(  !$              ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L!
M A0#%     @ PSIG59E<G",0!@  G"<  !,              ( !S $  'AL
M+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4    " ##.F=5.R +84T$  !Y$
M&               @($-"   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L!
M A0#%     @ PSIG59^@&_"Q @  X@P   T              ( !D P  'AL
M+W-T>6QE<RYX;6Q02P$"% ,4    " ##.F=5EXJ[',     3 @  "P
M        @ %L#P  7W)E;',O+G)E;'-02P$"% ,4    " ##.F=5JL0B%C,!
M   B @  #P              @ %5$   >&PO=V]R:V)O;VLN>&UL4$L! A0#
M%     @ PSIG520>FZ*M    ^ $  !H              ( !M1$  'AL+U]R
M96QS+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#%     @ PSIG5660>9(9 0
MSP,  !,              ( !FA(  %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&
2      D "0 ^ @  Y!,

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.2.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="tm2229838d1_8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://amicustherapeutics.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="tm2229838d1_8k.htm">tm2229838d1_8k.htm</File>
    <File>fold-20221107.xsd</File>
    <File>fold-20221107_lab.xml</File>
    <File>fold-20221107_pre.xml</File>
    <File>tm2229838d1_ex1-1.htm</File>
    <File>tm2229838d1_ex5-1.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2021q4</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "tm2229838d1_8k.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "tm2229838d1_8k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "fold-20221107_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "fold-20221107_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "fold-20221107.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"
     ]
    }
   },
   "elementCount": 59,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2021q4": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 22,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "fold",
   "nsuri": "http://amicustherapeutics.com/20221107",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "baseRef": "tm2229838d1_8k.htm",
      "contextRef": "From2022-11-07to2022-11-07",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00000001 - Document - Cover",
     "role": "http://amicustherapeutics.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "baseRef": "tm2229838d1_8k.htm",
      "contextRef": "From2022-11-07to2022-11-07",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of changes contained within amended document.",
        "label": "Amendment Description"
       }
      }
     },
     "localname": "AmendmentDescription",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://amicustherapeutics.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://amicustherapeutics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AnnualInformationForm": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.",
        "label": "Annual Information Form"
       }
      }
     },
     "localname": "AnnualInformationForm",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://amicustherapeutics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditedAnnualFinancialStatements": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.",
        "label": "Audited Annual Financial Statements"
       }
      }
     },
     "localname": "AuditedAnnualFinancialStatements",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://amicustherapeutics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://amicustherapeutics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CountryRegion": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Region code of country",
        "label": "Country Region"
       }
      }
     },
     "localname": "CountryRegion",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://amicustherapeutics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://amicustherapeutics.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAccountingStandard": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.",
        "label": "Document Accounting Standard"
       }
      }
     },
     "localname": "DocumentAccountingStandard",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://amicustherapeutics.com/role/Cover"
     ],
     "xbrltype": "accountingStandardItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r11",
      "r13",
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://amicustherapeutics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://amicustherapeutics.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://amicustherapeutics.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://amicustherapeutics.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentPeriodStartDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.",
        "label": "Document Period Start Date"
       }
      }
     },
     "localname": "DocumentPeriodStartDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://amicustherapeutics.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://amicustherapeutics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentRegistrationStatement": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a registration statement.",
        "label": "Document Registration Statement"
       }
      }
     },
     "localname": "DocumentRegistrationStatement",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://amicustherapeutics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentShellCompanyEventDate": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date of event requiring a shell company report.",
        "label": "Document Shell Company Event Date"
       }
      }
     },
     "localname": "DocumentShellCompanyEventDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://amicustherapeutics.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentShellCompanyReport": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.",
        "label": "Document Shell Company Report"
       }
      }
     },
     "localname": "DocumentShellCompanyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://amicustherapeutics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://amicustherapeutics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://amicustherapeutics.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://amicustherapeutics.com/role/Cover"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://amicustherapeutics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://amicustherapeutics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine3": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 3 such as an Office Park",
        "label": "Entity Address, Address Line Three"
       }
      }
     },
     "localname": "EntityAddressAddressLine3",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://amicustherapeutics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://amicustherapeutics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://amicustherapeutics.com/role/Cover"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://amicustherapeutics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://amicustherapeutics.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not.  Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.",
        "label": "Entity Bankruptcy Proceedings, Reporting Current"
       }
      }
     },
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://amicustherapeutics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://amicustherapeutics.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://amicustherapeutics.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://amicustherapeutics.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://amicustherapeutics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Elected Not To Use the Extended Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://amicustherapeutics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://amicustherapeutics.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://amicustherapeutics.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://amicustherapeutics.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://amicustherapeutics.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPrimarySicNumber": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.",
        "label": "Entity Primary SIC Number"
       }
      }
     },
     "localname": "EntityPrimarySicNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://amicustherapeutics.com/role/Cover"
     ],
     "xbrltype": "sicNumberItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://amicustherapeutics.com/role/Cover"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://amicustherapeutics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://amicustherapeutics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://amicustherapeutics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://amicustherapeutics.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://amicustherapeutics.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://amicustherapeutics.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_Extension": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Extension number for local phone number.",
        "label": "Extension"
       }
      }
     },
     "localname": "Extension",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://amicustherapeutics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://amicustherapeutics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_NoTradingSymbolFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a security having no trading symbol.",
        "label": "No Trading Symbol Flag"
       }
      }
     },
     "localname": "NoTradingSymbolFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://amicustherapeutics.com/role/Cover"
     ],
     "xbrltype": "trueItemType"
    },
    "dei_OtherReportingStandardItemNumber": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.",
        "label": "Other Reporting Standard Item Number"
       }
      }
     },
     "localname": "OtherReportingStandardItemNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://amicustherapeutics.com/role/Cover"
     ],
     "xbrltype": "otherReportingStandardItemNumberItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://amicustherapeutics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://amicustherapeutics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://amicustherapeutics.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_Security12gTitle": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(g) registered security.",
        "label": "Title of 12(g) Security"
       }
      }
     },
     "localname": "Security12gTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://amicustherapeutics.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://amicustherapeutics.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SecurityReportingObligation": {
     "auth_ref": [
      "r9"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.",
        "label": "Security Reporting Obligation"
       }
      }
     },
     "localname": "SecurityReportingObligation",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://amicustherapeutics.com/role/Cover"
     ],
     "xbrltype": "securityReportingObligationItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://amicustherapeutics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://amicustherapeutics.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://amicustherapeutics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 3
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r10": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r11": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310"
  },
  "r12": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r13": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r14": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r15": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r16": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r17": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r18": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  },
  "r19": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r5": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "g"
  },
  "r6": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12, 13, 15d"
  },
  "r7": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r8": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r9": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "15",
   "Subsection": "d"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001104659-22-115125-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001104659-22-115125-xbrl.zip
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MZ48DT_4$KPPUN9ZJ-2?-\EF/?L9T-"6_H<>[X_W));L=@GB7]^G.]^@KO?C
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M '$02 UQ"#Q^(X/&3S(*J;#J:IDWFKZR=$-SS(LY[-S60@$ZM_0 -MO4:**
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M*&24C# D#G4LGH'&XMDSQV*4S- G"I%OL3[=GEUW$\YFQ+_#+5@ O.\'DWI
M*L;>PGP;DMN%KM+<EX']4(W>8PJ%CK.%,R0/ W>6,$.3PJT!$T3$-O7:[KGS
M9/+UI:!!P-GC"12--D7PC7+^2<BE&%&BI:!)D0Z$9@F\1:"10)R3K)&+%H:O
MDF>6E,H7H"K/N> QA6)'G(OTR,-;[UDLJMY>CXK7CX2H^TI X2-.2H;%(JZ%
M,]3YS9[H!V+(QLM0#'PEH#% G* ,BT5=PZ_Z]F(TD^&Y^ -#*''$);B5TM!
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M>'>D?VQ H\G5^H%.J7)+(,9T9:YL8X_AFR5 <6B,4-^,!,90$:KS]I&N&WO
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M+'7P(;W5WT'#NRDZ&XD_"XJJ#&!]+6D!?.[XJ _JS6RHZD&]'5=V4$+!Y"Q
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M,]E1SJ\4QS>^DS$)%6F<N,";J.H90H5$]"!AEM3D&XE(._9*HJR:TW3,/-E
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M+*QL%]\A&"6>ZVNS695J0X(6J#<!*2W42,H[\V*Z7RS&X:Q)*W'ZL/#OXIA
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M,>?)9?748+R0/K*A<EI5'B=\#0AG\^W(EV^12%!6QZZ8/"Z/U!<F4I7<'M&
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M$]%$XPW#PW)6PS]S49H;HR!T>\)E@%>KJ&3>)E1^!4R @I?.P: ?P&QJ,9#
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MXFP58F4&05_YIYA?UN:BR&D_7]9W+_!/37FVFJDET</>1.;94:6S140\_+;
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M .EA/?$ZV(]P'G"F^#^S\WJ&3KY$/E':ZS61D.EMS%01%<:(FPLD>0OG0SE
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ME1VBMM.0+TLC"VY@D7/&TR$<&8,VQX)L+EHS1554K:/90N%?"U\>=02X3F=
M#Y_H@E8A_0A%KT.A./G]GG33[0_2[KL4VR4J'YSL,Y64J7QPLD]5WEE7=C2Z
M55?VY;O#@[=,V<&.K*\H\BR*5]',V3BXN]'2P%\QEU(1[ZVAOBY4[9ABN#"?
MN3Y6;3\ MZF&K6^"<(OMOF?D6:H75P>-_!4>FI8U89X:*EQALG7ZNC,C(]Z
M>'@4'W<%& PL0]-]FX+1^G+A2'8$M>:+CY$BK&5[%>N0 Q\)W:=5AUT$A-T%
M:W:[RYHH<<[!/[RDZ(;RT^3D#XP*2I5>EC""3D%G:/8R/%RI8B4TR!Y2&56
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M4!?-'9#I+4/6C_<A:PY9/]Z'K.^L+OW]]]TBT:%(78' E[*]]\N'64F!*4<
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MP8230^0@M]I\9LY=SD>*RG6)-8F!@F4K>W;ED33*@M[>5PA(Y4+GS)R./-W
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M[0N^">,0-,]IP#8'!M!\B4SQ?&13RQR,,\5=;[EWPJWM[RDV1$J!>J2Z*0]
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M+<^)_:=!<CNB?"PUU,ZR(;^XXR%4.5GOSLLTER218_HDDS:<2YZNX)L2<V;
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M*_ZC"9J[Y-"&R99#D8!@&+,)A$W0J;V#^9@2-XH8VT%7, +&22YD>'Z^W!D
M\>URV-6*HDLA]462%3?;$$?.JV(0EUK:%]X4I)431]1J9,;!VGKX%]^(5$I
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M[F$)DI.[Q26(DSD89G [C/E9Z.<ZZ2/9:!20A5Q1&T/CN:)NEZN>YIOA;X?
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MG>@S..9R9YL;6'>6#DA X)C(@[U7DK>)?].4H+@BXO'5#ZPW'[_A8\-6:$S
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MZ,US^RHZO;'^7U!+ 0(4 Q0    ( ,,Z9U5))ZS70@,  !,,   1
M      "  0    !F;VQD+3(P,C(Q,3 W+GAS9%!+ 0(4 Q0    ( ,,Z9U7D
M?5#Y_PH  &R'   5              "  7$#  !F;VQD+3(P,C(Q,3 W7VQA
M8BYX;6Q02P$"% ,4    " ##.F=5.W&.3UT'  #56   %0
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64$L%!@     &  8 BP$  $O<      $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
